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Abstract 
A significant body of literature has examined the impact of public health expenditure on mortality, 
using a global cross-section or panel of country-level data.  However, while a number of studies do 
confirm such a relationship, the magnitude of the impact varies considerably between studies, and 
several studies show statistically insignificant effects.  In this paper we re-examine the literature that 
identifies this effect using cross-country data.  Our analysis builds on the two instrumental variables 
(IV) approaches embodied by key publications in the field  W Bokhari et al. (2007) and Moreno-Serra 
and Smith (2015).  Using exactly the same data and econometric specifications as the published 
studies, we start by successfully replicating their findings.  However, further analyses using updated 
ĚĂƚĂĂŶĚ ‘ƐƚƌĞĂŵůŝŶĞĚ ?ĞĐŽŶŽŵĞƚƌŝĐƐƉĞĐŝĨŝĐĂƚŝŽŶƐ ?ƉůƵƐƐƚĂƚŝƐƚŝĐĂůĚĂƚĂŝŵƉƵƚĂƚŝŽŶĂŶĚĞǆƚĞŶƐŝǀĞ
robustness checks, reveal highly sensitive results.  In particular, the relevance of the IVs is seriously 
compromised in the updated data, leading to imprecise estimations of the relationship.  While our 
results should not be taken to imply that there is no true mortality-reducing impact of public health 
care expenditures on mortality, the findings do call for further methodological work, for instance in 
terms of identifying more suitable IVs or by applying other estimation strategies, in an effort to 
derive more robust estimates of the marginal productivity of public health care funding. 
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1. Introduction 
The question of whether, and if so, by how much, public health care expenditures impact on 
mortality outcomes has occupied and challenged researchers for some decades (Gravelle and 
Backhouse, 1987).  While it is hard to imagine that  W if the true relationship were in fact measurable 
 W public health care expenditures would not  ‘buy ? mortality reductions, all else equal, in reality there 
may well be  ‘weak links in the chain ? from spending to outcomes (Filmer et al., 2000).  Out of the 
significant body of empirical studies that have attempted to estimate the relationship, some 
previous studies confirm the expected sign and significance of the relationship, yet the magnitude of 
the impact varies considerably between studies, and several studies show statistically insignificant 
effects.  For instance, an influential study by Filmer and Pritchett (1999), using global cross-country 
panel data, found at best a small impact of public health care expenditures on under-five-mortality 
rates, with a 1% increase in spending leading to a  W statistically insignificant  W reduction in under-5 
mortality by 0.19%, and in infant mortality rates by 0.078%.  By contrast, Bokhari et al. (2007)  W using 
a cross-section of data from the year 2000 and an instrumental variable strategy that broadly follows 
Filmer and Pritchett (1999)  W find that a 1% increase in public health care expenditure significantly 
(both in statistical and economic terms) reduces under-5 mortality by between 0.25 and 0.42%, and 
maternal mortality by 0.42 to 0.52%.  Those findings have been reinforced very recently by Moreno-
Serra and Smith (2015), using again a large cross-country panel analysis with a novel estimation 
strategy that allows them to explicitly model the reverse causality from mortality onto spending.  
Some studies have also pointed to potential nuances in the relationship, e.g. in the sense that public 
spending matters most for the health of poor people in lower income countries (Bidani and Ravallion, 
1997), or that mortality is only reduced in response to public spending when the overall quality of 
governance in a country exceeds a certain threshold level (Wagstaff and Claeson, 2004; Rajkumar 
and Swaroop, 2008).  However, while a number of papers do claim to have established a causal 
relationship between expenditure and mortality outcomes, the magnitude of the impact varies 
considerably between studies. 
 
In light of these ambiguities, and in order to reflect potential changes in the relationship between 
public expenditure on health and mortality over time, we revisit the literature that identifies this 
effect using cross-country data. 
 
Re-estimating this relationship is important for several reasons.  To the extent that we are able to 
derive a robust empirical relationship, this would allow us to capture the marginal productivity of 
the publicly funded health care system, i.e. the opportunity costs of public health care spending, 
which in turn would be a crucial element to derive more useful cost-effectiveness threshold 
estimates than have hitherto been promoted, for instance in the widely used form of the 1-3 times 
per capita GDP rule-of-thumb.  This  ‘rule ? was initially proposed by the WHO Commission on 
Macroeconomics and Health (WHO 2001), and has subsequently been taken up by the World Health 
Organization (WHO 2015).  From there its use has spread massively, not least for lack of obvious 
other alternatives.  However, the limitations  W and potential harms  W of this approach have 
increasingly been recognised (Revill et al., 2014; Newall et al., 2014; Marseille et al. 2015).  Recent 
UK-focused research has shown how cost-effectiveness thresholds can empirically be estimated, 
starting from rigorous empirical estimates of the impact of spending on health outcomes (Claxton et 
al., 2015).  Cross-country based analysis of the kind presented in the present paper has the potential 
to inform empirically derived thresholds in countries world-wide, including low- and middle-income 
countries (LMICs) where the prioritization of health care resources to maximise population health 
gains is particularly warranted (Ochalek et al., 2015). 
 
In this paper we employ an empirical strategy rooted in the literature that has estimated the 
mortality effects of public health care expenditure using instrumental variable strategies  W by far the 
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most popular strategy to tackle endogeneity in this literature.  While we cannot fully reflect the 
specific approach taken in every single paper in this literature (see Table A10 for an overview of a 
select set of studies), we first examine the robustness of two exemplary studies  W by Bokhari et al., 
(2007) and Moreno-Serra and Smith (2015), henceforth referred to as BGG and MSS, respectively  W 
to new data, whilst preserving the papĞƌƐ ?ŽƌŝŐŝŶĂůŵŽĚĞůƐƉĞĐŝĨŝĐĂƚŝŽŶƐ.  In the second, major step of 
the analysis we then abstract slightly from the two exact specifications to construct panel data 
models using instrumental variables and covariates taken from our review of the existing literature.  
/ŶĚŽŝŶŐƐŽǁĞƐƚŝůůƉƌĞƐĞƌǀĞƚŚĞ ‘ƐƉŝƌŝƚ ?ŽĨƚŚĞƚǁŽĂƉƉƌŽĂĐŚĞƐ, by applying both a traditional 
approach to instrumentation (broadly following Bokhari et al (2007)) along with an application of 
Bruckner (2013), which is the approach followed by Moreno-Serra and Smith (2015).  (See Methods 
section for more details on the two approaches).  As part of the second step we also undertake a 
battery of robustness checks, not least to accommodate some other estimation approaches used in 
the literature (e.g. dynamic panel analysis).  Taken together we argue that following the empirical 
approaches proposed in these two studies  W first literally and then more generally  W allows us to 
capture the currently most promising approaches that have been used in this literature. 
 
We argue that Bokhari et al. (2007), apart from having become a highly cited paper in this literature, 
broadly represents the IV approach adopted in several such papers, starting from Filmer & Pritchett 
(1999) and Wagstaff and Claeson (2004).  Moreno-Serra and Smith (2015), by contrast, offer a 
different (though also IV based) approach that, for the first time in this literature, allows for an 
explicit assessment of the extent of reverse causality, running from mortality to health spending. 
 
By following the above broad strategy we comprehensively re-examine the robustness of the 
empirical relationship between public health care spending and mortality outcomes using cross-
country data, as it was presented in the main approaches used by the previous literature.  Across the 
two replicated studies, we find that in the majority of replication scenarios the effect of public health 
care expenditure on mortality is negative, although qualitative conclusions based on statistical 
significance vary and the magnitude of the impact is sensitive to revisions and updates in the data 
used.  New results from our  ‘streamlined ? model, using a traditional IV approach, are unreliable on 
account of the chosen instrument (per capita military expenditure of neighbouring countries) being 
found to not be statistically relevant.  For another  ‘streamlined ? model, using a novel identification 
strategy based on Bruckner (2013) and Moreno-Serra and Smith (2015), at least in some cases the 
estimated effects are broadly consistent with the previous literature, finding that public spending 
reduced mortality, although at generally lower effect magnitudes and with mixed degrees of 
statistical significance.  Our very mixed findings should not be taken to imply that the conclusions 
from the previous studies are necessarily invalid, and conclusions need to be seen in the light of the 
considerable methodological challenges (relating to data and econometric techniques) faced by this 
strand of research. 
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2. Methods 
Our basic model is specified as follows. We use country-level panel data including low-, middle- and 
high-income countries.  Our primary focus is to estimate the causal impact of public health 
expenditure on mortality outcomes. To this end, we consider the following simple linear model: 
 Ǥ O? O?ǣ୨୲ ൌ Ⱦ୨ ൅ Ⱦଵ୨୲ ൅ ܆୨୲ᇱ ઺ ൅ ߝ௝௧ 
 
MO is mortality and EX is public healthcare expenditure in country j at time t.  The vector X 
represents covariates.  Our main goal is to estimate Ⱦଵ, which represents the expenditure elasticity 
when the natural logarithm of MO and EX are used in the regression model i.e. the effect of a 1% 
increase in expenditure on the % change in mortality.  While health care expenditure may reduce 
mortality, policymakers may increase health expenditure in response to an increase in mortality  W i.e. 
the idea of reverse causality.  Also, mortality and health expenditure may be correlated with a third 
variable (which is often not observed in the data), which gives rise to omitted variable bias on the 
estimated coefficients.  Given these concerns in this observational setting, we need an exogenous 
variation of expenditure EX to identify the causal impact of EX on MO (which is represented by the 
coefficient Ⱦଵ). 
 
Following both BGG and MSS, we use an instrumental variable approach. BGG and MSS use distinct 
IV approaches which differ in their econometric specification and also in their strategy in identifying 
the causal impact of expenditure.  Employing more than one approach allows us to assess the 
robustness and sensitivity of the estimated impacts to different econometric approaches using the 
same data.  Hence we start our analyses by replicating the analyses of BGG and MSS respectively, 
using their original data as well as our updated data.  In order to assess the extent to which their 
conclusions may be driven by their specific features of the models (e.g. choice of variables and data 
years), we also construct a streamlined version of econometric model with our own set of variables 
(based on a review of the literature), and augment the two distinct approaches to estimate the 
impact of health expenditure on mortality outcomes. 
 
2.1 BGG model 
BGG use a more traditional IV approach that may be seen as broadly representative for a range of 
existing studies published before.  However, this particular study uses cross sectional data from 2000 
(as opposed to panel data from multiple years), and also employs a structurally motivated model 
that investigates the impact of health expenditure as well as GDP per capita on mortality. 
 
The main outcome variables in the BGG model are log of under-5 mortality and log of maternal 
mortality.  There are four key independent variables which are treated as endogenous.  The 
endogenous variables include GDP per capita, public health care expenditure and two interaction 
terms involving public health expenditure: 1) public health expenditure and deviation in donor 
funding on basic health from historical mean; and 2) public health care expenditure and the quantity 
of paved roads per unit area in the country (as a proxy of economic development).  The model 
includes the following covariates: log of proportion of non-literate (proxy of education); log of 
quantity of paved roads per unit area; log of donor funding; and log of proportion of population with 
access to improved sanitation. 
 
BGG use a number of instrumental variables in their first stage regression with the four endogenous 
variables.  dŚĞ/sƐŝŶĐůƵĚĞ P ? ?ůŽŐŽĨŶĞŝŐŚďŽƵƌƐ ?ŵŝůŝƚĂƌǇĞǆƉŶĚŝƚƵƌĞƉĞƌĐĂƉŝƚĂ ?ĂŶĚŝƚƐŝŶƚĞƌĂĐƚŝŽn 
with a) deviation in donor funding on basic health from historical mean and b) the quantity of paved 
roads per unit area ? ? ?ŝŶĚŝĐĂƚŽƌƐŽĨƋƵĂůŝƚǇŽĨƉŽůŝĐŝĞƐĂŶĚŝŶƐƚŝƚƵƚŝŽŶƐ ?ďĂƐĞĚŽŶtŽƌůĚĂŶŬ ?Ɛ
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annual assessment of countries), and again its interaction with deviation in donor funding from 
historical mean and paved road rate; and finally 3) the log of the consumption-investment ratio. 
 
2.2 MSS model 
MSS use a more novel IV approach inspired by Bruckner (2013), which explicitly takes into account 
the reverse causality from mortality to health expenditure.  In this approach, as the first step, we 
estimate the reverse causality  W the impact of mortality on health care expenditure: 
 Ǥ O? O?ǣ୨୲ ൌ ɀ୨ ൅ ɀଵ୨୲ ൅ ܆୨୲ᇱ ઻ ൅ ௝߳ 
 
Note that we use the same set of covariates (vector X) in this reverse causality model.  Once we 
estimate ɀଵ by a panel fixed effect instrumental variable regression, we calculate the following 
residual: 
 Ǥ O? O?ǣ୨୲כ ൌ ୨୲ െ ɀଵෞ୨୲ 
 
Assuming the instruments used in Eq. (2) are valid and relevant, this residual is now orthogonal to 
the variation of mortality.  In the second step, we use this residual as an IV for health expenditure in 
Eq. (1) to estimate the impact of health expenditure on mortality. 
 
The main outcome variables in the MSS study are: under-5 mortality, adult female mortality, and 
adult male mortality. MSS specify four endogenous indicators of health expenditure: a) public health 
care expenditure; b) private out-of-pocket health care expenditure; c) expenditure from private 
voluntary health insurance; and d) immunization coverage.  We therefore estimate Eq. (2) and 
calculate the residual in Eq. (3) for each endogenous variable separately, but estimate the impact of 
these variables in one main regression Eq. (1) with four endogenous variables.  Since the panel data 
are clustered at country level, the estimation of the standard errors takes this data structure into 
account through the use of cluster-robust standard errors. 
 
In the MSS model the covariates include: GDP per capita, primary education enrolment rate, 
proportion of population under 14, and proportion of population over 65.  Note that, in contrast 
with BGG, in the MSS analysis GDP per capita is treated as an exogenous control variable.  In the 
streamlined model below we follow this simplification of the model because our main purpose is 
specifically to estimate the impact of health expenditure on mortality, which we pursue using a 
reduced form specification. 
 
2.3 Streamlined model 
As described above, BGG and MSS have specific features in terms of data, selection of variables, and 
strategy to estimate causal impacts.  For instance, BGG use cross-sectional data whereas MSS use 
panel data1; they use different set of health expenditure variables (some of which are not our 
primary interest) and also different sets of covariates.  These particular features might have led to 
                                                          
1
 On the whole there is good reason to expect that all else equal, using panel data allows for more credible inference than 
cross-sectional data as the former allows the researcher to control for unobserved time invariant factors at country level 
directly via a fixed effects estimator. This can be important if such a source of unobserved heterogeneity is both correlated 
with health spending and mortality outcomes as it would then reduce the need for finding appropriate IVs for the health 
spending variable (assuming of course that there is no other source of endogeneity). Alternatively, if the omitted time 
invariant variable is not correlated with health spending, one can use random effects models instead of fixed effects for a 
gain in efficiency. Generally, both types of panel estimators are an improvement over simple cross-sections. The problem, 
and hence the trade-off in panel vs cross-section data comes from not being able to obtain reliable time series on all 
variables of interest. This can happen when some of the variables of interest have been provided by data dissemination 
agencies by interpolating for missing values. 
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different magnitudes of the main estimates or even their conclusions. In order to still follow the 
 ‘ƐƉŝƌŝƚƐ ?ŽĨƚŚĞƚǁŽĂƉƉƌŽĂĐhes represented by these studies without strictly adhering to their highly 
ƐƉĞĐŝĨŝĐŵŽĚĞůƐ ?ǁĞĐŽŶƐƚƌƵĐƚŽƵƌŽǁŶŵŽĚĞůƐƉĞĐŝĨŝĐĂƚŝŽŶƐ ?ǁŚŝĐŚǁĞƌĞĨĞƌƚŽĂƐ ‘ƐƚƌĞĂŵůŝŶĞĚ ?
models) as described below. 
 
2.3.1 Data structure and panel data analysis for streamlined model 
We use country level panel data from 1995 to 2011.  This means that in applying a traditional IV 
approach we complement the above-described, cross-sectional BGG analysis by incorporating 
further, more recent data points, and by allowing for country-level fixed effects in the model and 
estimate a within-country impact of health expenditure.  This will additionally take into account any 
unobserved, time invariant country-level heterogeneity.  Furthermore, the country level fixed effect 
is also likely to account for some of the (unobserved) heterogeneity from factors that vary only 
slowly over time (and particularly in shorter time series), such as cultural factors and institutional 
ƋƵĂůŝƚǇ ?D^^ ?ƐŽƌŝŐŝŶĂůƐƚƵĚǇƵƐĞƐĚĂƚĂĨƌŽŵ ? ? ? ?ƚŽ ? ? ? ? ? We therefore include more recent years 
(up to 2011) in our Bruckner IV approach analysis (Bruckner, 2013).  Descriptive statistics of the 
streamlined model are given in Table 3. 
 
2.3.2 Outcome variables 
We follow MSS in choosing our outcome variables.  We use: under-5 mortality, adult female 
mortality, and adult male mortality.  However, while MSS use under-5 mortality estimated by the 
Institute of Health Metrics and Evaluation, we use estimates produced by the United Nations (as in 
BGG).  This is because more data are available in the UN mortality data (up to 2011) than in the 
IHME data (up to 2010). 
 
2.3.3 Health care expenditure 
While BGG and MSS specified a number of endogenous variables, in our streamlined model we focus 
only on public health care expenditure following a reduced form approach.  In particular, in line with 
MSS, in our main model we treat GDP per capita as an exogenous control variable to keep the model 
parsimonious.2  Moreover, although BGG include two interaction terms involving the rate of paved 
road and the amount of donor funding on basic health, we drop these interaction terms from our 
streamlined model because some of the data are not available, and also because these factors are 
not of primary interest to us.3  ^ŝŵŝůĂƌůǇ ?ǁĞĞǆĐůƵĚĞƚŚƌĞĞŽĨD^^ ?ƐŬĞǇĞǆƉůĂŶĂƚŽƌǇǀĂƌŝ ďůĞƐ ?ŝ ?Ğ ?
out-of-pocket expenditure, private insurance expenditure and immunization coverage, for the same 
reason.4 
                                                          
2
 Appendix Table A9 presents the model where per capita GDP is treated as an endogenous variable. Following BGG, we 
used the consumption-investment ratio as the instrument for per capita GDP. The estimated effect of per capita GDP is 
negative and in some cases the effect is statistically significant, i.e. higher national income reduces mortality. The 
estimated impact of public health expenditure in this model is largely similar to the estimates presented in the main paper. 
ůƐŽ ?ƵƐŝŶŐ'' ?ƐŽƌŝŐŝŶĂůĚĂƚĂĂŶĚĨŽůůŽǁŝŶŐƚŚĞŝƌƐƉĞĐŝĨŝĐĂƚŝŽŶ ?ǁĞĞƐƚŝŵĂƚĞĚƚŚĞŵŽĚĞůǁŝƚŚƉĞƌĐĂƉŝƚĂ'WƚƌĞĂƚĞĚĂƐ
exogenous variable. We find that the impacts of public expenditure on the mortality outcomes are largely maintained (the 
impact is -0.390 (SE=0.128) for under-5 mortality; and it is -0.607 (SE=0.190) for maternal mortality). These additional 
results imply that assuming per capita GDP as exogenous should not substantially bias the estimation of the impact of 
public healthcare expenditure on mortality outcomes in our data. 
3
 hƐŝŶŐ'' ?ƐŽƌŝŐŝŶĂůĚĂƚĂ ?ǁĞĞƐƚŝŵĂƚĞĚƚŚĞ'' ?ƐŵŽĚĞůǁŚŝůĞĞǆĐůƵĚŝŶŐƚŚĞŝŶƚĞƌĂĐƚŝŽŶƚĞƌŵƐĂŶĚĂůƐŽĂƐƐƵŵŝŶŐƉĞƌ
capita GDP to be exogenous. The impacts of public expenditure on mortality outcomes are qualitatively maintained (the 
impact is -0.419 (SE=0.096) for under-5 mortality; and it is -0.565 (SE=0.163) for maternal mortality). 
4
 Dropping private expenditure might lead to misspecification of the model and therefore bias the estimated impact of 
public healthcare expenditure. However, as shown in Table 4, dropping the private expenditure from the original MSS 
specification does not affect the impact of public expenditure to a substantive degree. Also, in Appendix Table B1, we 
estimate the impact of total healthcare expenditure (which includes both public and private expenditure) on mortality, and 
find that the results are similar to the principal estimation results presented in the main text (Table 6). This might be 
because public healthcare expenditure accounts for a majority of healthcare resources in many (though by no means all) 
countries and thus the potential bias from omitting private expenditure may be negligible. 
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2.3.4 Instrumental variables 
Based on our review of the existing literature, we use instrumental variables, which have been 
shown to be relevant in the previous literature, including BGG and MSS.  However, since we 
estimate within-country impact by using fixed effect models, our instrumental variables should vary 
over time.  Therefore we cannot use time-invariant IVs (i.e. certain dimensions of governance quality 
and their interactions) in the streamlined model. 
 
As explained in the sections 2.1 and 2.2, in the traditional IV analysis we need instruments for public 
health care expenditure, whereas the Bruckner IV analysis requires instruments for mortality.  In the 
ƚƌĂĚŝƚŝŽŶĂů/sĂƉƉƌŽĂĐŚ ?ǁĞƵƐĞŶĞŝŐŚďŽƵƌƐ ?ŵŝůŝƚĂƌǇĞǆƉĞŶĚŝƚƵƌĞ(in % of GDP) ĂŶĚŶĞŝŐŚďŽƵƌƐ ?
public health expenditure (in % of GDP) as instrumental variables (Filmer and Prichett, 1999; 
Wagstaff and Claeson, 2004).5 6 
 
Our instruments in the Bruckner IV approach include per capita emission of CO2 and number of 
deaths by conflict per 100,000 people, following MSS.  ƐĂƐĞŶƐŝƚŝǀŝƚǇĐŚĞĐŬǁĞĂůƐŽƵƐĞt,K ?ƐĚĂƚĂ
on external causes of death as additional IVs predicting exogenous variations in mortality.7  Test 
statistics for the relevance of the IVs are presented and discussed in the Results section. 
 
2.3.5 Covariates 
Previous studies (including but not limited to BGG and MSS) use a variety of covariates, and there 
appears to be no common set of covariates that has been applied in all studies.  In this study we use 
the following principle-based selection of covariates. We conduct a literature review of the related, 
cross-country type studies.  We identified and reviewed 11 studies and recorded covariates from 
each study (Afridi and Ventelou, 2013; Akinci et al. 2014; Anyanwu and Erhijakpor, 2009; Bokhari et 
al. 2007; Farag et al. 2013; Filmer and Pritchett, 1999; Gani, 2009; Hu and Mendoza 2013; Moreno-
Serra and Smith, 2015; Rajkumar and Swaroop, 2008; and Wagstaff and Claeson, 2004).8  From the 
full set of candidates we obtain a shortlist of covariates in the following way: first, we exclude 
variables if we decide they can be outcomes of health expenditure (e.g. number of hospital beds), as 
including those variables would cause selection bias in the regression (Angrist and Pischke, 2009). 
Second, we follow Hauck et al. (2015) in our selection of further covariates:  
 
1) We drop a variable if, in the currently available data, more than 60% of observations 
between 1995 and 2011 are missing across years and countries; 
2) In order to avoid multi-collinearity among covariates, we calculate the pair-wise 
correlation between the de-meaned candidate variables and drop one of the variables, if the 
correlation coefficient is above 0.6.9  
                                                          
5
 In preliminary analyses we also employed a 'just identified' model with one instrumental variable, where we used per 
capita military expenditure of neighbouring countries for the single endogenous variable (i.e. public health care 
expenditure) in the main model. We found this single instrument was too weak in terms of the first stage F statistics (F is 
less than 1 in most cases). 
6
 A rationale for the IV is that if neighbouring countries spend more on military equipment and services, the domestic 
government would increase or decrease military expenditure to maintain the military balance, which would affect the level 
of healthcare expenditure per capita. Note that this IV has been widely used in the previous literature - see Anyanwu and 
Erhijakpor (2009), Bokhari et al. (2007), Filmer and Prichett (1999), and Wagstaff and Claeson (2004). 
7
 External cases of death include: transport accidents, smoke and fire, poisoning, falls, drowning, and assault, which largely 
randomly occur across the population. 
8
 These studies were collected using a  ‘snowballing ? strategy, in which we started by looking at the reference list of BGG 
and MSS studies for relevant studies, then once we found a related study (initially judged by title, and then by full text), we 
included the study in our review and also checked the reference list of the study for further references. We iterated this 
process for several times, thus converging towards the set of studies included in our review. 
9
 De-meaned variables (i.e. we calculate the mean of ĂŐŝǀĞŶǀĂƌŝĂďůĞĨŽƌĞĂĐŚĐŽƵŶƚƌǇĂŶĚƚŚĞŶƐƵďƚƌĂĐƚƚŚĞĐŽƵŶƚƌǇ ?Ɛ
mean over the observed time period) are used because we use fixed effect models, in which de-meaned variables are 
analysed in the regression. 
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Our final set of covariates is as follows: GDP per capita, primary education enrolment rate, 
proportion of population under 14, proportion of population over 65, rate of paved road, access to 
improved sanitation, urbanisation, and two measures of efficiency of governance (government 
efficiency and control of corruption). See Table 3 for more detail. 
 
Finally, in the streamlined model we use log-scale variables (which is consistent with BGG but not 
MSS). All analyses are conducted using Stata 13 MP. 
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3. Data 
For the most part the main data sources we make use of are those used in the two papers we are 
being guided by here  W BGG and MSS  W both of which use data sources that have been commonly 
employed in the relevant literature.  For the original replication of the published results the authors 
of the original articles generously allowed us full access to the original data (and codes) that were 
used for the published results of those papers.  When updating the data to include the most recently 
available ones, we also used, wherever accessible, the sources indicated in the two papers.  It should 
be noted that for most of the variables even the older data are regularly revised in the publicly 
available data sources, and it is not always possible to obtain older versions of the database. 
 
dŚĞŵĂũŽƌŝƚǇŽĨŽƵƌĚĂƚĂĐŽŵĞƐĨƌŽŵƚŚƌĞĞǁŝĚĞůǇƵƐĞĚƐŽƵƌĐĞƐ PƚŚĞtŽƌůĚĂŶŬ ?ƐtŽƌůĚ
Development Indicators (WDI), the World Health OƌŐĂŶŝǌĂƚŝŽŶ ?Ɛ'ůŽďĂů,ĞĂůƚŚKďƐĞƌǀĂƚŽƌǇ ?ĂŶĚƚŚĞ
/ŶƐƚŝƚƵƚĞŽĨ,ĞĂůƚŚDĞƚƌŝĐƐĂŶĚǀĂůƵĂƚŝŽŶ ?Ɛ ‘'ůŽďĂů,ĞĂůƚŚĂƚĂǆĐŚĂŶŐĞ ? ?The sources, definitions, 
and downloaded data of all the variables we used in our empirical analysis study are given in 
Appendix Table A1. 10 
 
Tables 1 and 2 give the descriptive statistics of each of the composed datasets we use in our 
analysis: First, for the original and updated data analysis of the BGG paper (Table 1), and second for 
the MSS paper (Table 2).  In these tables, there are some notable discrepancies between original 
data and updated data, which could be attributable to data updates by the data providers, or to 
differences in the exact metric used for a given variable.11  In Table 1, the original data consist of 127 
countries whereas the updated data consist of 238 countries.  Similarly, in Table 2, the original data 
consist of 158 countries whereas the updated data consist of 250 countries.  Appendix Table C1 and 
C2 present the descriptive statistics for the subset of updated data using the same set of countries as 
in the original data.  The discrepancies between the original and updated data become smaller.  In 
the results section we examine the impacts of using different versions of GDP data on the regression 
results (see Appendix Tables A2-A5 for detailed results). 
 
3.1 Data imputation 
Although we use the most up-to-date data that is currently available in the public domain, significant 
numbers of missing values do remain.  The sample size in different studies (BGG, MSS and others) 
varies significantly (from around 100 to 150 countries) as a result, depending on the selection of 
variables and versions of the data source used in their analyses.
                                                          
10
 EŽƚĞƚŚĂƚĚĂƚĂŽŶŵŽƌƚĂůŝƚǇĂƌĞĨƌŽŵƚŚĞtŽƌůĚĂŶŬ ?Ɛt/ĚĂƚĂďĂƐĞ ?ŝ Ğ ?ĨŽƌĂĚƵůƚĨĞŵĂůĞŵŽƌƚĂůŝƚǇƌĂƚĞ ?ĂĚƵůƚŵĂůĞ
mortality rate, maternal mortality rate, and under-5 mortality rate). The under-5 mortality data available in the WDI 
database are based oŶhŶŝƚĞĚEĂƚŝŽŶƐ ?ĞƐƚŝŵĂƚĞƐ ?/,DŚĂǀĞƉƌŽĚƵĐĞĚĂůƚĞƌŶĂƚŝǀĞĞƐƚŝŵĂƚĞŽĨƵŶĚĞƌ-5 mortality, and it 
does not appear obvious which one of the two is closer to the truth (Alkema and You, 2012). 
11
 For instance, the updated data has GDP per capita based on purchasing power parity in 2011 constant dollars, but MSS 
used GDP per capita based on purchasing power parity in 2005 constant dollars, and BGG used GDP per capita in 2000 
international dollars (also based on purchasing parity). It should be noted that Table 1 and 2 compare outcomes from 
different set of countries. 
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Table 1: Descriptive statistics of BGG data (original data and updated data)
 
Notes: 
* 
In this column the analysis include as many countries as possible (max available number of countries is 238) from the updated data sources. 
 ?/ŶƚŚĞŽƌŝŐŝŶĂůĚĂƚĂ ?'WƉĞƌĐĂƉŝƚĂƵƐŝŶŐŝŶƚĞƌŶational dollars as of 2000 is used. In the updated data, GDP per capita using constant US dollars 2011 (PPP adjusted) is used.  
 ?/ŶƚŚĞŽƌŝŐŝŶĂůĚĂƚĂ ?ŐŽǀĞƌŶŵĞŶƚŚĞĂůƚŚĞǆƉĞŶĚŝƚƵƌĞƉĞƌĐĂƉŝƚĂ ?ŝŶƚĞƌŶĂƚŝŽŶĂůĚŽůůĂƌƐĂƐŽĨ ? ? ? ? ?ŝƐƵƐĞĚ ?/ŶƚŚĞƵƉĚĂƚĞĚĚĂta, government health expenditure per capita in 2005 constant 
dollars is used.  
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Table 2: Descriptive statistics of MSS data (original data and updated data)
 
Notes: 
* 
In this column the analysis include as many countries as possible (max available number of countries is 229) from the updated data sources.  
 ?/ŶƚŚĞŽƌŝŐŝŶĂůĚĂƚĂ ?ŐŽǀĞƌŶŵĞŶƚŚĞĂůƚŚĞǆƉĞŶĚŝƚƵƌĞƉĞƌĐĂƉŝƚĂ ?ŝŶƚĞƌŶĂƚŝŽŶĂůĚŽůůĂƌƐĂƐŽĨ ? ? ? ? ?ŝƐƵƐĞĚ ?/ŶƚŚĞ updated data, government health expenditure per capita in 2005 constant 
dollars is used. 
 ?/ŶƚŚĞŽƌŝŐŝŶĂůĚĂƚĂ ?'WƉĞƌĐĂƉŝƚĂƵƐŝŶŐŝŶƚĞƌŶĂƚŝŽŶĂůĚŽůůĂƌƐĂƐŽĨ ? ? ? ?ŝƐƵƐĞĚ ?/ŶƚŚĞƵƉĚĂƚĞĚĚĂƚĂ ?'WƉĞƌĐĂƉŝƚĂƵƐing constant US dollars 2011 (PPP adjusted) is used.  
dŚĞǀĂƌŝĂďůĞ ‘ĞĂƚŚďǇĐŽŶĨůŝĐƚ ?ĚŽĞƐŶŽƚŚĂǀĞĂŶǇŵŝƐƐŝŶŐǀĂůƵĞƐ ?dŚĞŽƌŝŐŝŶĂů^/WZ/ĚĂƚĂ ?ƐĞĞƉƉĞŶĚŝǆdĂďůĞ ? ?ůŝƐƚƐƚŚĞcases of conflicts and the number of deaths where they observed. 
Following Morreno-Serra and Smith (2015), we assume that there were not conflicts (and therefore no deaths) if the original data do not list any information for a given country. 
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Table 3: Descriptive statistics of the streamline model data (1995-2011) 
  
Table 1 and 2 also show the number of missing values in each variable in the updated data, for the 
replication of the BGG model and the MSS model, respectively.  For the BGG data, except for the 
World Bank in-house data and the data on donor funding on basic health which we failed to obtain12 
the missing values in the updated data are up to 66% (of 229 countries in the updated data), with 
the missingness in the illiteracy rate and the rate of paved roads being particularly high.  This means 
that without imputation or without amending the modelling specification we cannot replicate the 
BGG analysis with a sufficient number of observations.  On the other hand, for the MSS data the 
extent of missingness is relatively moderate: over 10% of observations are missing for all variables 
(except for `death by cŽŶĨůŝĐƚ ? ? ?ĂŶĚŵŽƌĞƚŚĂŶ ? ?A?ŽĨǭprimary ĞĚƵĐĂƚŝŽŶĞŶƌŽůŵĞŶƚƌĂƚĞ ?ĂƌĞ
missing. 
 
Given the large numbers of missing values in the data (for both BGG and MSS), we decide to 
implement a standard  ‘multiple imputation by chained equations ? (MICE) approach, following Hauck 
et al. (2015) ?ĂŶĚĂǀĂŝůĂďůĞĂƐĂ^ddĐŽŵŵĂŶĚ ? ‘ŵŝ ? ? (StataCorp, 2013).13  MICE is a regression 
based imputation method, in which variables with missing values are regressed on the other 
variables in the dataset, and then the predicted value of the missing part will be imputed.  This 
procedure is sequentially applied to the other variables with missing values, one at a time.  In 
particular, again following Hauck et al. (2015), we use a predictive mean matching technique 
                                                          
12
 While in the original BGG data, per capita donor funding for health promotion from the Development Assistance 
Committee (DAC) of the Organization for Economic Co-operation and Development (OECD) in year 1998 (which we failed 
to update) is used. However, we obtained a qualitatively similar data, i.e. data on per capita amount of Development 
Assistance for Health (DAH), available at the Institute of Health Metrics and Evaluation database, which we use in the 
replication analysis of BGG using data from year 2010. 
13
 See also Perkins and Neumayer (2014) for an application of MICE in combination with instrumental variables regressions. 
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(Landerman et al., 1997).  According to this technique, a missing value is imputed using non-missing 
values of samples with similar predictive mean.  In the present study we use three neighbours of the 
predictive mean for the imputation (White et al. 2011).  Also, since the data are clustered at country 
and year level, we take this into account in the analysis by including year and country fixed effects in 
the imputation equations.  Throughout the present paper, we replicate the procedure and generate 
50 imputed datasets, and hence conduct 50 separate regression analyses at a time, before the 
estimates are merged into the final estimation result.14  Finally, if all values of the variables in the 
regression models are missing for a country, we drop the country from the analysis.15 
 
Although in principle all variables in the regression model should be included in the imputation 
equation, in the present study we do not impute our instrumental variables in the chained multiple 
imputation.  This is because a key condition in an instrumental variable approach is that instruments 
should not be correlated directly with outcome variable (capturing the exclusion restriction) 
(Wooldridge 2010).  Imputing the instrumental variables by (partly) using the outcome variable 
would make it difficult to justify the exclusion restriction.  Instead, for the instrumental variables we 
impute missing values with the mean of the values from neighbouring observations from the same 
country, i.e. when the value in time t is missing, we impute the mean of the values in t-1 and t+1.  If 
all values are missing in the country, we again do not impute the missing values, and therefore that 
country is dropped from the final estimation sample. 
 
Finally, we assessed the performance of the multiple imputations.  We randomly chose 1000 non-
missing observations, and artificially dropped them from the working data.  We imputed the 
dropped observations (as well as the originally missing observations) using the MICE technique, and 
then compared the imputed values with the original non-missing values.  For all variables used in the 
streamlined models, the multiple imputations worked well  W the mean difference between the 
original and imputed value was consistently less than one standard deviation point value of each 
variable. 
  
                                                          
14
 Once the number of replications is specified, this procedure is automĂƚŝĐĂůůǇĐŽŶĚƵĐƚĞĚƵƐŝŶŐƚŚĞ ‘ŵŝ ?ĐŽŵŵĂŶĚŝŶ^ƚĂƚĂ
13 MP. For more detail, see StataCorp (2013). The rule-of-thumb suggests that the number of replications should about 
correspond to the percentage of missing values in the data. Since less than 50% of the data are missing in our data (Table 1, 
2 and 3), the number of replications is considered to be sufficiently large. 
15
 In the present study we conduct regression analyses for multiple outcome variables (under-5 mortality and adult 
mortality) separately. However, in the imputation equation we include the other outcome variable, e.g. we use among 
other variables under-5 mortality to impute missing values of adult mortality. Also, in the regression analysis we use the 
imputed dependent variables. We checked the main regression results by not using the imputed dependent variables but 
instead using the un-imputed dependent variable, and confirmed that our main conclusion is not affected (details not 
reported here). 
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4. Results 
In what follows we first present the results of the replication exercise for each of the two 
approaches  W BGG (section 4.1.1) and MSS (section 4.1.2).  Subsequently, we present the results of 
the streamlined version of either approach  W in section 4.2.1 for BGG and in section 4.2.2 for MSS. 
 
4.1 Replication results 
4.1.1 Replication of BGG 
Table 4 starts by replicating the results of the original approaches used in BGG. Column (1) provides 
the results as they were given in the original paper.  As we obtained the original data (as well as the 
command files) from the authors of both papers, we then tried to replicate the results using exactly 
the same specification as in the original specification.  The results of this replication correspond 
exactly to those in the original paper.  Table 4 also shows additional test statistics for the first stage 
regression for multiple endogenous variables: in addition to the standard F statistic, we present an 
augmented F-statistic allowing for multiple endogenous variables (Sanderson and Windmeijer, 2013), 
as well as <ůĞŝďĞƌŐĞŶĂŶĚWĂĂƉ ?ƐtĂůĚƌŬ&ƐƚĂƚŝƐƚŝĐĨŽƌƵŶĚĞƌ-identification (Kleibergen and Paap, 
2006), showing that the instruments are ƌĞĂƐŽŶĂďůǇ ‘strong ? (the rule-of-thumb threshold for F is 10). 
 
As the next step we replace the original data from the BGG paper by the revised data that is 
available in the relevant data sources as of August 2015, but for exactly the same year that was 
covered in the paper, i.e. 2000 (see Column (2) in Table 4).  This exercise entailed a reduction in the 
sample size, down from 127 to 66 countries (due to a particularly large number of missing values in 
the literacy and paved road variables), reducing the comparability of those specific estimates, with 
respect to the results of the original BGG paper.  The reduction in sample size also provides the case 
for boosting the sample size using imputation methods.16  We use two different ways of imputation 
in Table 4  W ĨŝƌƐƚǁĞĨŝůůƚŚĞŐĂƉƐďǇƵƐŝŶŐ'' ?ƐŽƌŝŐŝŶĂůĚĂƚĂĚŝƌĞĐƚůǇ ?ǁŚĞƌĞǀĞƌƚŚĞƵƉĚĂƚĞĚĚĂƚĂ
from readily available sources does not have this information (see Column (3)); second, we use a 
statistical multiple imputation method (MICE) to fill the gaps in the currently available data (see 
Column (4)).17  The results in columns (3) and (4) of Table 4 give results that are qualitatively 
comparable but quantitatively different from the original research  W the size of the impacts of the 
public health expenditure is remarkably larger in the analyses using the updated data with 
imputation.  For under-5 mortality, the original BGG study found that a 1% increase in expenditure 
will reduce mortality by 0.341% (column (1)).  However, when applying MICE to the updated data, 
the magnitude of the impact is about twice as large as in the original study (the elasticity is -0.601).  
A similar, but relatively modest increase in the size of the impact is found for maternal mortality 
(from -0.519 to -0.618).  It is important to note that the relevance of the same instrumental variables 
is now very weak in the updated data, implying the results from the original BGG analysis (1) are 
more credible than those found in (3) and (4). 
  
                                                          
16
 '' ?ƐŽƌŝŐŝŶĂůĚĂƚĂĂƌĞŵĂŶƵĂůůǇŝŵƉƵƚĞĚƵƐŝŶŐsimilar data sources (e.g. CIA World Factbook), and by using information 
from adjacent years, where data for the year of their analysis (2000) was missing. By contrast, here we use a statistical 
method (i.e. multiple imputations) to impute missing values. 
17
 We note that the large number of missing variables comes in the readily available data sources, compared to the data 
used by BGG, is due to extra-efforts expended by BGG in filling the gaps manually by using information from other data 
sources (e.g. CIA fact book) and by interpolation, in the case of variables that are likely to not fluctuate much from year to 
year (e.g. paved roads). 
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Table 4: Replication of BGG analysis 
 
Notes: Model (1) shows the results as published and replicated; Model (2) shows the results from updated data (year 2000) 
without imputation; Model (3) shows the results from updated data (year 2000), imputed using the original data where 
missing; Model (4) shows the results from updated data with multiple imputation; Model (5) shows the results from 
updated data (year 2010) without imputation;  Model (6) shows the results from updated data (year 2010) with multiple 
imputation. 
 
In Model (5) and (6), since we do not have access to the World Bank in-house data on quality of governance, we impute the 
ǀĂƌŝĂďůĞƵƐŝŶŐƚŚĞ'' ?ƐŽƌŝginal data (as of 2000).  
 
In Table 1, non-literate rate and paved road rate exhibit high rates of missing values in the updated data (81.9% and 47.9% , 
respectively). Since these variables are not likely to vary overtime, we impute the data for 2000 if there are any 
information available either in 1998, 1999, 2001 and 2002 (two years before and after 2000). The same imputation of the 
literacy variable is applied to the updated data from 2010.  
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The BGG original analysis and our replications use data from 2000.  In columns (5) and (6) we analyse 
the updated data for 2010.18  With and without multiple imputations of the data, the estimated 
impacts of public health expenditure are greater than the estimated impacts from the 2000 data (in 
column (6) with multiple imputations, the magnitude of the impact is about -0.9 for both under-5 
and maternal mortality). 
 Sensitivity checks 
By way of sensitivity checks of the above replication analysis using the 2000 data, starting from the 
original BGG data, we sequentially update only one variable at a time, in order to assess which 
variable is causing the discrepancies between the estimation result using the original and updated 
data.  The results are summarised in Appendix Table A2 and A3.  The size of the impact of public 
health expenditure displays sensitivity with the impact on under-5 mortality now ranging from -
0.257 to -0.459 (Appendix Table A3). 
 
4.1.2 Replication of MSS 
When trying to replicate the results of MSS using the original data (column (1) in Table 5), the model 
failed to produce the results.  By comparing the results to those obtained using an older version of 
Stata, for which we were able to exactly replicate the original results, it turned out that this 
significant discrepancy to the original results is the result of an updated version of the Stata code 
used in the IV fixed effect estimation - xtivreg2 (Schaffer, 2010; we used the July 2015 version).19  
Therefore we modified the MSS approach in that we dropped three of the four endogenous 
variables, leaving only our key variable of interest  W public health expenditure  W as the one 
endogenous variable.  Re-running the MSS model, using exactly the same data as in the original 
paper, we obtain largely similar coefficients on the public health expenditure variable as in MSS (see 
column (2) in Table 5). 
 
As was done with the BGG analysis above, we then substitute the original data from the MSS paper 
by the revised data that is available in the relevant data sources as of August 2015, but for exactly 
the same years as those covered in the papers, i.e. 1995-2008 (see column (3) of Table 5).  Following 
this procedure produces less robust results compared to those based on the original data: the 
coefficient of interest remains statistically significant but reverses sign, suggesting a counter-
intuitive relationship between expenditures and mortality rates, i.e. health expenditure increases 
mortality.  This is likely the result of the less than ideal instruments for mortality (per capita CO2 
emission and number of deaths by conflict), as suggested by the very low relevance of the 
instruments in the first stage regression (F-statistics is less than 4 in all models), reducing the 
reliability of the estimates. 
  
                                                          
18
 The descriptive statistics of the 2010 data are presented in Appendix Table C3. 
19
 The updated code rejects the model as it detects multi-collinearity between the four instrumental variables used in the 
first stage regression of the MSS model. We used different versions of - ivreg2 - and  W ranktest  W commands which are both 
used within  Wxtivreg2  W routine. In the analyses presented throughout the present study is based on - ivreg2 - version 
4.1.08 26 July 2015 and  W ranktest  W version 1.3.05 22 Jan 2015. Using older version of the routine - ivreg2 - version 2.2.08 
15 Oct 2007 and  W ranktest  W 1.1.02 15 Oct 2007, we successfully replicate the results published in the MSS study.  
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Table 5: Replication of MSS analysis 
 
Notes: 
x Model (1) shows the results as published 
x Model (2) shows the results (public healƚŚĞǆƉĞŶĚŝƚƵƌĞŽŶůǇ ?ĨƌŽŵŽƌŝŐŝŶĂůĚĂƚĂƵƐŝŶŐƵƉĚĂƚĞĚ^ƚĂƚĂ ?  ?ĂƵƚŚŽƌƐ ?
own estimation) 
x Model (3) shows the results from updated data (1995-2008) without imputation 
x Model (4) shows the results from updated data (1995-2011) without imputation 
x Model (5) shows the results from updated data (1995-2008), imputed using the original data where missing 
x Model (6) shows the results from updated data (1995-2008) with multiple imputation 
x Model (7) shows the results from updated data (1995-2011) with multiple imputation 
 
However, once we impute the data again, first by filling the (now very few) gaps in the data with 
values from the original MSS data (Column (5)) and second by using multiple imputation techniques 
(Column (6) and (7), now with considerably larger sample size), the sign of the coefficients reverse 
again to the expected direction, but their magnitude still varies considerably between the 
specifications, and the instruments for mortality continue to be  ‘weak ?, i.e. they produce only fairly 
low F-statistics, according to the benchmarks suggested by Stock and Yogo (2005) and Sanderson 
and Windmeijer (2013).20  
 
                                                          
20
 /ŶƚŚĞƉƌĞƐĞŶƚĂŶĂůǇƐŝƐǁĞĨŽůůŽǁ^ĂŶĚĞƌƐŽŶĂŶĚtŝŶĚŵĞŝũĞƌ ?Ɛ&ƐƚĂƚŝƐƚŝĐƐĨŽƌƌĞůĞǀĂŶĐĞŽĨƚŚĞŝŶƐƚƌƵŵĞŶƚƐ ?/ĨƚŚĞ
endogenous variable(s) are just identified i.e. the number of instruments equals the number of endogenous variables, this 
augmented F statistic coincides with the standard F statistic. 
A: Under 5 mortality
(1) (2) (3) (4) (5) (6) (7)
Public health expenditure -13.193** -13.779** 6.759*** -41.302 -0.486 -4.251*** -0.013
(0.018) (5.794) (1.915) (37.414) (0.321) (1.498) (0.082)
Out-of-pocket health expenditure -6.143 . . . . . .
(0.507) . . . . . .
Privately pooled health expenditure 2.685 . . . . . .
(0.594) . . . . . .
Immunization coverage -2.203* . . . . . .
(0.073) . . . . . .
1st stage F of reverse causality estimate 3.16 3.070 0.150 0.057 0.770 0.937 1.355
1st stage F of main estimate . 7.402 21.979 1.285 2630.650 40.332 5.61E+07
Country 153 153 155 159 166 161 163
N 1397 1398 1366 1602 1569 2217 2583
B: Adult female mortality
(1) (2) (3) (4) (5) (6) (7)
Public health expenditure -2.583** -3.957** 12.224** 7.483 0.552 -1.041** -0.591*
(0.050) (1.552) (5.908) (4.639) (0.468) (0.479) (0.310)
Out-of-pocket health expenditure 5.153 . . . . . .
(0.161) . . . . . .
Privately pooled health expenditure -23.385** . . . . . .
(0.040) . . . . . .
Immunization coverage -9.841** . . . . . .
(0.030) . . . . . .
1st stage F of reverse causality estimate 7.19 7.341 3.763 2.321 4.195 3.148 4.985
1st stage F of main estimate . 4857.69 36.830 34.091 71586589.1 226878.2 110959.4
Country 148 148 154 158 165 160 163
N 1222 1223 1359 1677 1562 2203 2699
C: Adult male mortality
(1) (2) (3) (4) (5) (6) (7)
Public health expenditure -2.210** -2.944*** 8.854** 6.148* 0.646 -0.620 -0.542**
(0.025) (1.026) (3.704) (3.475) (0.552) (0.382) (0.238)
Out-of-pocket health expenditure 8.731 . . . . . .
(0.172) . . . . . .
Privately pooled health expenditure -15.545** . . . . . .
(0.016) . . . . . .
Immunization coverage -7.858** . . . . . .
(0.020) . . . . . .
1st stage F of reverse causality estimate 11.60 12.021 2.270 1.487 5.173 1.859 2.615
1st stage F of main estimate . 13790.4 89.679 52.797 4.216e+08 499648.8 243220.4
Country 148 148 154 158 165 160 163
N 1222 1223 1359 1677 1562 2203 2699
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 Sensitivity checks 
Similarly to section 4.1.1, we assess which variable is causing the discrepancy between the 
estimation results using the original and updated data, by replacing every variable in the original 
data with the corresponding variable in the updated data.  Appendix Tables A4 and A5 show the 
results.  For under-5 mortality, replacing CO2 emission and GDP per capita lead to counter-intuitive 
estimates, while for adult female/male mortality, replacing education and public health expenditure 
lead to counter-intuitive results.21  Similar to the BGG analysis above, the magnitude of the impact 
varies considerably upon updating only one variable at a time: the effect estimates range from 
+1.105 to -14.774 (Appendix Table A5). 
 
4.2 Streamlined model analysis 
We develop streamlined models in which we focus on estimating the impact of public health care 
expenditure using approaches that are broadly (though no longer literally) in line with those 
employed in the previous literature, including specifically BGG and MSS. 
 
Also, we use a structured approach to select the covariates.  The Methods section has outlined the 
streamlined model in more detail.  Table 6 presents the key results of our streamlined models, using 
different strategies to estimate the causal impacts of public health expenditure: fixed effect 
instrumental variable approach, pooled cross-section IV approach with additional (time invariant) 
instruments.  Comparing the estimation results with and without the statistical multiple data 
imputation, we note again the considerable numbers of missing values in the raw data (see Table 3 
for more details on missing values).22  
 
4.2.1 ^ƚƌĞĂŵůŝŶĞĚŵŽĚĞůĂŶĂůǇƐŝƐ'' ?ƚŚĞ ?ƚƌĂĚŝƚŝŽŶĂů/sĂƉƉƌŽĂĐŚ ? 
In the case of the traditional IV approach, using the streamlined model, the results do not confirm 
the large and significant impacts found in the BGG study.  In the first stage regression, the relevance 
of the instrumental variable (log of per capita military expenditure of neighbouring countries) is too 
weak to identify the causal effect, and hence the large standard errors of the point estimate, making 
the model essentially invalid. 
 
  
                                                          
21
 As explained in the Data section, the original MSS study use per capita GDP in 2005 constant US dollars (PPP adjusted), 
whereas in the updated data analysis we use per capita GDP in 2011 constant US dollars (PPP adjusted). 
22
 The publicly available mortality data are frequently estimated rather than directly observed (Alkema and You, 2012). In 
order to (partially) avoid the potential problem of serial correlation due to the data estimation, we analysed the same 
econometric model with more sparse, five-year interval data (1995, 2000, 2005, and 2010). The result is presented in 
Appendix Table A8. The results are qualitatively similar to the results in Table 6. 
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Table 6: Traditional IV and Bruckner IV approach using streamlined model 
 EŽƚĞ PdŚĞĞƐƚŝŵĂƚĞƐƉƌĞƐĞŶƚĞĚŝŶƚŚĞĐŽůƵŵŶƐůĂďĞůůĞĚ ‘ƉŽŽůĞĚĐƌŽƐƐƐĞĐƚŝŽŶ ?ŝŶĐůƵĚĞŵŽƌĞƚŝŵĞŝŶǀĂƌŝĂŶƚŝŶƐƚƌƵŵĞŶƚĂů
variables in addition to original set of time varying instruments. For Traditional IV approach, additional instruments for 
public health expenditure include the legal origin of the country: British, French, Socialist, German and Scandinavian laws 
(Rajkumar and Swaroop, 2008; Hu and Mendoza, 2013). For Bruckner IV approach, additional instruments for mortality 
include indicators of climate zoŶĞďĂƐĞĚŽŶ<ŽƉƉĞƌ ?ƐĐůĂƐƐŝĨŝĐĂƚŝŽŶĂŶĚŵĂůĂƌŝĂĞĐŽůŽŐǇŝŶĚĞǆ ?>ŽƌĞŶƚǌĞŶĞƚĂů ? ? ? ? ?ĂŶĚ
Kizsewski et al. 2004) 
 
Sensitivity checks 
Since the results in Table 6 (columns under  ‘Traditional IV ?) highlight the limitations in the existing 
instruments with the updated data, we have sought to improve the quality of the predictive power 
of the instruments by experimenting with different functional forms of the original instruments and 
by using alternative ones, following suggestions from the literature.  The outcome of this exercise is 
presented in Appendix Table A6 for the traditional IV approach. Despite these efforts, we fail to find 
results that would confirm our expectations. 
 
Next, in the streamlined model, per capita GDP is treated as an exogenous variable, whereas in the 
original BGG specification it is endogenous, and there is hence a concern that this could have led to 
biased estimates due to model misspecification.  To examine this possibility, we conduct an analysis 
that does treat per capita GDP as another endogenous variable.  Following BGG, the consumption-
investment ratio was used as the additional instrumental variable for per capita GDP.  Appendix 
Table A9 shows the results. Although it is interesting to see that the models with the multiple 
imputations show that higher per capita GDP significantly reduces under-5 mortality, we fail to find 
that public health expenditure reduces mortality outcomes. 
 
4.2.2 ^ƚƌĞĂŵůŝŶĞĚŵŽĚĞůĂŶĂůǇƐŝƐD^^ ?ƚŚĞ ?ƌƵĐŬŶĞƌ/sĂƉƉƌŽĂĐŚ ? 
As for the Bruckner IV approach, the results using multiple data imputation appear mixed as well, 
showing the expected negative and statistically significant impacts of public health expenditure in 
particular for under-5 mortality, though less so for adult mortality (see Table 6 under  ‘Bruckner IV ?).  
The instrumental variables turn out less relevant in a statistical sense (informed by F statistics of the 
first stage regression).  The magnitude of the elasticity is substantially smaller than what was implied 
A: log under 5 mortality
(1) (2) (3) (4) (5) (6) (7) (8)
log Public health expenditure 0.159 0.682 0.683 0.053 0.110** -0.224** -0.185* -0.063
(0.753) (0.782) (0.629) (0.200) (0.047) (0.103) (0.098) (0.040)
First stage F of reverse equation . . . . 1.262 3.707 3.584 2.335
First stage F of main equation 0.245 0.748 0.785 1.761 2323.615 57.13 2413.079 79102.720
Data imputation No Yes No Yes No Yes No Yes
N 661 2601 648 2601 666 2631 634 2631
B: log adult female mortality
(1) (2) (3) (4) (5) (6) (7) (8)
log Public health expenditure 0.203 0.319 0.025 -0.037 1.836** 0.023** -0.063 -0.030
(1.102) (0.421) (0.377) (0.211) (0.792) (0.012) (0.060) (0.051)
First stage F of reverse equation . . . . 0.096 4.445 6.940 4.201
First stage F of main equation 0.108 0.748 0.803 1.761 6.040 11345226.8 1424.858 1872.009
Data imputation No Yes No Yes No Yes No Yes
N 642 2601 631 2516 647 2590 618 2590
C: log adult male mortality
(1) (2) (3) (4) (5) (6) (7) (8)
log Public health expenditure 0.194 0.241 0.147 -0.159 0.337*** -0.148* -0.037 -0.009
(1.188) (0.322) (0.345) (0.157) (0.077) (0.084) (0.057) (0.031)
First stage F of reverse equation . . . . 1.293 3.696 8.135 5.004
First stage F of main equation 0.108 0.748 0.803 1.761 82.351 29.99 2050.833 11412.165
Data imputation No Yes No Yes No Yes No Yes
N 642 2601 631 2516 647 2590 618 2590
Traditional IV Bruckner IV
Fixed effect Pooled cross section Fixed effect Pooled cross section
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in the original studies.  For instance, where intuitive direction and statistical significance are 
achieved, the magnitude of the impact on under-5 mortality is -0.224, and that on adult male 
mortality is -0.148, i.e. a 1% increase in expenditure leads to a reduction of mortality by 0.224 or 
0.148%. 
 
Sensitivity checks 
Testing a set of different IVs, in an effort to overcome the limitations in the existing instruments with 
the updated data (see Appendix Table A7), provides the same conclusions as ŝŶƚŚĞ ‘ƚƌĂĚŝƚŝŽŶĂů/s ?
case above: we obtain insignificant or counter-intuitive results, the relevance of the instruments 
remains low and the discrepancy to the results in the original studies is large. 
 
4.3 Specification and robustness checks 
In Appendix B1, we conduct further specification checks of the analysis based on the streamlined 
model (both Traditional and Bruckner IV approaches).  Notably, the main models presented above 
have examined the impact of a change in expenditure on a change in mortality in the same year.  
Also, in the main model we only address the impact of public health expenditure, ignoring other 
sources of health care spending.  First, we investigated the lagged (t-1, t-2, or t-5) impacts of public 
health expenditure on current mortality outcomes, with only one lag-specification included at a time.  
Also, we examined the impact of total health expenditure (public and private expenditure).  For 
more detailed description, see Appendix B.1.  The results of the analyses are presented in Appendix 
Table B1.  For the Traditional IV approach, again the estimation results are not reliable due to low F 
statistics.  For the Bruckner IV approach, when multiple imputation is applied, we again find a small, 
negative and statistically significant impact for under-5 mortality  W the size of elasticity is around -0.1 
to -0.2 for t-1,t-2 and t-5 models, and the impact diminishes upon increasing the number of lags.  For 
adult female and male mortality, the effect is even smaller and statistically indistinguishable from 
zero.  Similarly, the impacts of total expenditure were not statistically significant or intuitive, except 
for the case ŽĨƌƵĐŬŶĞƌ ?Ɛ/sĂƉƉƌŽĂĐŚ (see Block D, Column (4) of Table B1), where the elasticity of 
(current) total health expenditure on under-5 mortality is about -0.3. 
 
We then allow for lagged structure in the estimation of the impact of expenditure.  We include 
current and lagged health expenditure (t-1, t-2 and t-3) in the same econometric model and 
estimated the conditional impacts of expenditure at each period on current mortality outcomes.  
The results are summarised in Appendix Table B2.  The results from the Traditional IV approach 
show non-significant impacts of contemporaneous as well as any lagged public health expenditure in 
all models.  For the Bruckner IV approach, when the multiple imputations are applied, the impact of 
contemporaneous public health expenditures (column (4)) is negative and statistically significant for 
under-5 mortality and adult male mortality.  However, the impacts of lagged public health 
expenditure (conditional on contemporaneous expenditure) are small and largely statistically 
insignificant. 
 
The final set of specification checks involves different assumptions for the identification of causal 
impacts.  Although in the main analysis we use instruments that were demonstrated to be 
statistically relevant in the previous cross-country data studies, we fail to confirm this in the updated 
data and in the streamlined model specification.  This could suggest that alternative analytic 
approaches are called for that do not rely on the identification of suitable external instruments.  
Following this idea, we pursue two approaches: first, we use lagged health expenditure to avoid 
reverse causality while still using fixed effect modelling to take into account time-invariant country 
heterogeneity23; second, we incorporate a dynamic structure into the model and construct a set of 
                                                          
23
 We make a stronger assumption about exogeneity of lagged health expenditure here than the previous models 
presented in this section. In fact, lagged health expenditure is predetermined but not necessarily exogenous.  
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IVs from observations from previous years  W a dynamic panel data approach (Blundell and Bond, 
1998).  The results of the estimations from the two approaches, with and without the data 
imputation, are presented in Table Appendix B3. In the table, Block A, B and C use only fixed effect 
effects to estimate the effect of contemporaneous and lagged health expenditure.  In Block D, the 
estimates from Blundell-Bond estimation are presented.  The estimates of the impact of health 
expenditure turn out rather mixed, though overall the magnitudes of the impacts, whether 
statistically significant or not, are much smaller than expectations based on the results from BGG 
and MSS.24 
 
  
                                                          
24
 The results of the model using the imputed data should be interpreted with caution. As P-values of AR tests indicate, 
there is no second-order serial correlation. However, the Hansen test indicates that the over-identifying restriction is not 
valid, meaning that some of the IVs are endogenous. 
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5. Discussion 
In this paper we have sought to comprehensively re-examine the robustness of the empirical 
relationship between public health care spending and mortality outcomes using cross-country data, 
as it was presented in the main approaches used by the previous literature.  We have based our 
analysis on the data and approaches embodied by two recent key publications in the field  W by 
Bokhari et al. (2007) and Moreno-Serra and Smith (2015).  We started by quite successfully 
replicating the published results, using the exact same data used by the studies.  Results were more 
nuanced once we made use of data for the same year(s) as in the original study but available from 
publicly accessible sources at the time of data retrieval (August 2015).  In  ‘updating ? the data in this 
way, while still following the specific estimation strategies from the original papers, we also 
employed different imputation strategies to fill major data gaps for some variables.  On the whole 
we found the BGG-based results to still hold qualitatively, though with increased effect size and with 
weaker performance of the instruments.  By contrast, the MSS-based results were substantively 
affected, and the relevance of the instruments did deteriorate, producing less resemblance to the 
original results.  Across the two studies, in the majority of replication scenarios the effect of public 
health care expenditure on mortality was found to be negative, although qualitative conclusions 
based on statistical significance vary and the magnitude of the impact is sensitive to revisions and 
updates in the data used. 25 
 
In a further step, we abstracted from the specific estimation strategies in the original papers, among 
others in order to follow the  ‘spirit ? of the approaches used, without the need for overly strict 
adherence to their idiosyncratic features, and in order to capture some commonalities with other 
previous studies in this field.  We thus constructed our  ‘streamlined ? versions of the two approaches, 
complemented by a battery of robustness checks, as well as some changes to the specifications to 
accommodate certain other empirical approaches used in the literature (e.g. dynamic panel analysis).  
In sum, the results showed that in the traditional IV model our instrument for public health care 
expenditure (per capita military expenditure of neighbouring countries) is not statistically relevant 
and thus the IV estimation coefficients become unreliable.  For the Bruckner IV streamlined model, 
at least in some cases the estimated effects were broadly consistent with the previous literature, 
finding that public spending reduced mortality, although at generally lower effect magnitudes and 
with mixed degrees of statistical significance. 
 
Our very mixed findings should not be taken to imply that the conclusions from the previous studies 
are necessarily invalid.  Countries covered in the published data and in our updated data do indeed 
differ and therefore it is to be expected that the analysis leads to different conclusions. Nevertheless, 
our findings do highlight the potential lack of generalisability of the results to different settings. 
 
Our conclusions need to be seen in the light of the considerable methodological challenges faced by 
this strand of research, many of which may form the basis of a potential research agenda in this area, 
as discussed below. 
 
5.1  Data limitations 
The data used for the replication of the two key papers have been obtained directly from the 
authors of the paper in the case of Bokhari et al (2007) and from data made available via the web 
appendix for the Moreno Serra & Smith (2015) paper.  With very few exceptions, this data is in 
principle available from readily and freely ĂĐĐĞƐƐŝďůĞĚĂƚĂƐŽƵƌĐĞƐ ?Ğ ?Ő ?ƚŚĞt,K ?Ɛ'ůŽďĂů,ĞĂůƚŚ
                                                          
25
 Similar sensitivities of the results to updates in the underlying data have been encountered by Easterly et al. (2004), 
Roodman (2008), Clemens et al. (2012), and Roodman (2015) in the context of replicating the results from the literature on 
the impact of aid on economic growth. 
22  CHE Research Paper 128 
KďƐĞƌǀĂƚŽƌǇĂŶĚƚŚĞtŽƌůĚĂŶŬ ?ƐtŽƌůĚĞǀĞůŽƉŵĞŶƚ/ŶĚŝĐĂƚŽƌƐ ? These (as well as several other 
publicly accessible databases) are also the data sources we have used when updating and expanding 
the data employed in our empirical estimates.  While the data from these sources represent the 
most comprehensive ones available and have been (and most certainly will be) used in numerous 
well-published studies26, they are not without quality concerns that may affect the reliability of our 
impact estimates.  This is the case despite the considerable and laudable efforts that international 
organizations or research institutes have invested to try and establish common standards of how 
data should be defined and collected.  The degree to which quality issues are present will vary by 
indicator and across countries.  For instance, the data collection for one of our key variables  W GDP 
per capita  W should be approximately similar across countries given longstanding efforts to ensure 
consistent definition of this measure. 
 
Measurement error is likely more severe in the case of our key independent variable (i.e. public 
health expenditures).  ƐƚŚĞt,K ?ƐŵĞƚŚŽĚŽůŽŐŝĐĂůďĂĐŬŐƌŽƵŶĚŶŽƚĞ ?World Health Organization, 
2012) to their Global Health Expenditure database acknowledges, there are major gaps in the data 
delivered to WHO from countries (which, if it is delivered, is typically taken on at face value), with 
the gaps then being filled by various forms of interpolation27, extrapolation, imputation and 
estimation. 
 
Random measurement error in the health expenditure variable would normally bias the estimates of 
the impact on mortality towards the null, while random measurement error in our dependent 
variable (mortality) would produce higher standard errors of the impact estimates, reducing the 
statistical significance of the results (Wooldridge, 2010).28  As health expenditure enters as a right 
hand side variable in our regression model, it is likely that a valid instrumental variable strategy 
could reduce some of the bias resulting from such measurement error.  In our case though, for many 
of the empirical models the instruments used were weak  W and it is this that has arguably been a far 
greater problem in our set of estimates, compared to data quality issues.  Moreover, there are at 
least two sources of measurement error  W one embedded in the numbers reported to the data 
collecting agencies (i.e. WHO), and an additional one as a result of the (not always fully replicable) 
imputation approaches adopted by such agencies.  In this case it is at least conceivable (though very 
hard to tell for certain) that measurement error in the health expenditure variable may account for 
the weakness of the instrumentation in the first stage estimates. 
 
Arguably, measurement error is far more severe in the case of our dependent variables of interest, 
i.e. the under-5 and gender-specific adult mortality-rates  W the underlying problem being the often 
complete absence of functioning vital registration systems in particular in many low income 
countries (Alkema and You, 2012).  In response, ĂŶŝŵƉƌĞƐƐŝǀĞƌĞƐĞĂƌĐŚ ‘ŝŶĚƵƐƚƌǇ ?ŚĂƐemerged, 
developing and applying sophisticated modelling methods to fill the mortality data gaps statistically.  
The fact that different research teams find considerable differences in, for instance, their under-5 
mortality estimates for many LMICs does, however, underscore the measurement problem at hand.   
Short of obtaining the  ‘perfect ? data (which will never happen), there are, however, ways in which 
more purposefully selected, specific data sources would be worthwhile using, if there is reason to 
believe that they provide better quality data, and even at the cost of reducing the country coverage.  
Examples on the mortality side might include using data from Demographic and Health Surveys only 
or on the expenditure side to focus on information from detailed IMF Government Finance Statistics, 
ƚŚĞtŽƌůĚĂŶŬ ?ƐWŽǀĞƌƚǇƐƐĞƐƐŵĞŶƚƐĂŶĚWƵďůŝĐǆƉĞŶĚŝƚƵƌĞZĞǀŝĞǁƐ ?see e.g. Gupta et al., 2003).    
                                                          
26
 The literature in other development areas, e.g. on the role of aid on economic growth, has been shown to suffer from 
similar data challenges (Easterly et al. 2004; Roodman, 2008). 
27
 'ŝǀĞŶƚŚĂƚƐŽŵĞŽĨƚŚĞŽƌŝŐŝŶĂůǀĂƌŝĂďůĞƐĂƌĞĞƐƚŝŵĂƚĞĚƵƐŝŶŐƉƌĞǀŝŽƵƐǇĞĂƌƐ ?ŽďƐĞƌǀĂƚŝŽŶƐ ?in Appendix Table A8 we 
present the same analysis based on the streamlined model where we use quinquennial data.  
28
 Note also that in case the measurement error is non-random but constant over time, then the fixed effects approach 
would resolve this problem. 
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5.2 Methodological limitations 
There are at least three methodological issues to be borne in mind. 
 
First, following the previous literature that predominantly accounts for country-level heterogeneity 
and for endogeneity of health expenditure and mortality, we have employed a panel fixed effect 
approach, combined with instrumental variables techniques.  Incorporating country fixed effect in 
the model means that we compromise statistical power because the estimation relies only on 
within-country variations in health care expenditure and mortality.  Because there are relatively 
small variations in these variables over time, and also because the analysis often relies on  ‘weak ? 
instrumental variables, our methods (though being standard in the literature) may be of insufficient 
power to statistically detect the impact.  This potential downside of the fixed-effect approach, 
however, has to be weighed up against the likely considerable benefits of controlling more 
adequately for endogeneity through the regression control over unobserved heterogeneity in time-
invariant characteristics and also in factors that change slowly over time such as cultural factors or 
the quality of institution. 
 
Second, our results using the multiple imputations (MI) should be interpreted with caution.  
Although MI has been widely adapted in the applied statistic literature, its applications in health 
econometric models (in particular as part of instrumental variables approaches) have been rare 
(Perkins and Neumayer, 2014).  We carefully construct our imputation so that it does not violate the 
exclusion restriction assumption in the IV approach.  Yet detailed statistical properties of the 
application of the MI approach should be expanded upon in future research.  That said, and as we 
showed, the alternative of not imputing the data would mean that the econometric analysis would 
have to do without a considerable number of countries with any missing values in the model 
specifications, producing a highly unrepresentative sample and causing selection bias, the impacts of 
which in terms of main effects are a priori unknown (though likely significant).  At the same time, it 
must be noted that the statistical imputation increases the likelihood of measurement error in the 
regressions, thereby augmenting the impact estimates as well as the standard errors. 
 
Third, the instrumental variable technique has been the standard workhorse for causal analysis in 
the relevant literature.  As in the present study, the validity and relevance of the instruments can 
generally be questioned  W i.e. some instruments occasionally prove to be good in a statistical sense, 
but that could be sensitive to choice of data and other variables in the model.  Furthermore, it 
should be noted that the instrumental variable approach does not necessarily provide average 
treatment effects (ATE), which would be the key quantity of interest, but instead it gives the local 
average treatment effect (LATE), in which the impact of health expenditure is identified only for the 
subset of countries for which expenditure is actually affected by the instruments (Angrist and 
Imbens, 1995; Angrist et al., 1996).  In the literature it is common to assume homogeneity of the IV 
impact, rather than allowing for heterogeneity of the impacts across countries, so that the estimated 
IV impacts conveniently represents ATE, despite that in practice it is hard to believe that the impacts 
of expenditure will be common across countries.  For simplicity, the present study, as well as the 
previous studies in the literature, focuses on homogeneous impacts and abstains from discussing 
likely differences between the ATE and LATE in this context. 
 
5.3 Policy implications 
The primary policy question is whether or not greater public health care expenditures improve 
population health.  The two prominent studies  W BGG and MSS  W claim that health expenditures do 
reduce mortality, and that the magnitude of the effect is considerable, hence supporting greater 
publicly funded health coverage across countries.  However, the cross-country based work 
presented here (as well as some of previous research, e.g., Filmer and Pritchett 1999) shows that the 
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magnitude and precision of this effect is sensitive to the choice of data and econometric methods.  
Our results do not necessarily suggest that policies expanding public health expenditure do not save 
lives at all. Rather, our results confirm the common problems in cross-country data analysis  W that 
the noise in the cross country data may be so large that the current econometric methods could 
sometimes fail to robustly detect the health gains at global level. 
 
Another important implication of the analysis would be the extent to which our estimates reliably 
inform marginal productivity of healthcare systems across countries  W the key variable that would be 
needed to inform country-specific cost-effectiveness thresholds (Ochalek et al 2015).  In light of the 
limited robustness to changes in model specification and in data of the empirical findings, coupled 
with imprecise estimation (due to weak IVs), our results again may not uncover the true (if any) 
productivity of healthcare systems across countries, and therefore further improvement in either 
data, empirical methods, or even research design are required.29 
 
5.4 Implications for future research 
Future research should involve the improvement in both the methods for the analysis of cross 
country data and in data quality.  Global efforts to obtain finer data should improve the data quality 
over time.  Some arguably  ‘better ? data already exists, if at the cost of a considerably smaller sample 
of countries; for example, international household surveys  ?Ğ ?Ő ?ƚŚĞtŽƌůĚĂŶŬ ?Ɛ>ŝǀŝŶŐ^ƚĂŶĚĂƌĚ
Measurement Surveys) do provide finer data on health and household healthcare spending at more 
granular level (e.g. observations at household level), which could potentially overcome some of the 
key limitations in the cross country data. 
 
Since the impact of public health expenditure on mortality could also be heterogeneous across 
countries, future research should explore such heterogeneity.  The BGG model does allow for 
differential impacts, conditional on the level of economic development (proxied by the proportion of 
paved roads) and on the amount of donor funding for health.  Using the updated data for the year 
2000 in the BGG specification, Appendix Figure A1 summarises the distribution of the impacts of 
public health expenditure on mortality.  We find that the impacts for under-5 mortality are 
considerably more homogenous than for maternal mortality.  Similarly, Wagstaff and Claeson (2004) 
found that the mortality-reducing impact of public expenditure becomes evident only once the 
quality of governance exceeds a certain threshold level.  It may hence be worthwhile to assess 
possible additional factors that mitigate or promote the impact of public health expenditure, 
including, for instance, baseline mortality.  Quantile treatment effect models could be useful to test 
and quantify the impacts of public health expenditure across countries (Chernozhukov, and Hansen 
2005). 
 
Another possibility would be to use within-country data to investigate the domestic impact of health 
expenditure on health outcomes.  Although there are is some such research in high income countries 
(for example, Martin et al., 2008; Card et al., 2009; Claxton et al., 2015), the evidence is still limited 
in LMICs, where policy issues relating to universal health coverage become more relevant and also 
healthcare resources are generally scarce, except for some existing studies in major countries such 
as India (Bhalotra, 2007; Farahani et al., 2010). 
 
At the same time, our findings add further weight to the case for journals to require authors to 
submit their data along with their paper, so that the data becomes permanently available to future 
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 An online tool based on Ochalek et al. (2015) has been made available at: 
https://www.york.ac.uk/media/che/documents/Calculating%20cost%20per%20DALY%20averted%20thresholds%20for%20
LMICs.xlsm, which enables users to enter new estimates of the elasticity of health outcomes with respect to public health 
care expenditure, or to carry out sensitivity analysis when using existing published estimates when estimating cost-
effectiveness thresholds for LMICs. 
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scholars, thereby allowing for the discrepancies resulting from retrospective corrections to be traced 
to changes in the data.  The problem we encountered when trying to replicate the exact original MSS 
results using an updated, revised version of a Stata command (xtivreg2) also suggest that whenever 
authors use a public-domain user-written program, that the journal should require them to post the 
program as well as the data and relevant Do-files. 
 
Likewise, the agencies producing and publishing the data would benefit research by making available 
each version of the data, rather than just the latest one that would supersede all previous ones.  The 
producers of such data could also usefully increase the degree of transparency about the exact 
methods that have been used in imputing gaps in the underlying data, and indeed the extent to 
which imputation has been undertaken. 
 
Finally, the current literature is largely based on an instrumental variable approach in estimating 
causal impacts of health expenditure, despite the fact that instruments could be sometimes 
questioned (even if statistically relevant occasionally, they are not always theoretically convincing).  
An alternative approach would be to use actual policy variations in healthcare expenditure to inform 
the impact estimation.  Examples of sources of such variations include expansion of public insurance 
schemes (see Acharya et al., 2012 for a comprehensive review), funding decision rules in healthcare 
(Dykstra et al., 2015), and large scale field or natural experiments that involve the provision of 
additional healthcare resources/funding (Wagstaff, 2011; Olken et al., 2014).  Carefully evaluating 
those policy and experimental shocks on expenditure could possibly provide more transparent and 
robust evidence. 
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Appendix A 
 Table A 1: List of sources of updated data 
 Table A 2: BGG analysis using the original data  
 Table A 3: BGG analysis using the original data: updated data are imputed using original data 
where missing 
 Table A 4: MSS analysis using the original data 
 Table A 5: MSS analysis using the original data: updated data are imputed using original data 
where missing 
 Table A 6: Traditional IV approach (with streamlined model) using different specifications of 
instrumental variables 
 Table A 7: Bruckner IV approach (with streamlined model) using different specifications of 
instrumental variables 
 Table A 8: Regression analysis based on data from 1995, 2000, 2005, and 2010 only 
(replication of the analysis in Table 6, first column with fixed effect IV model) 
 Table A 9: Traditional IV approach (with streamlined model) in which logGDP per capita is 
treated as an endogenous variable 
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Table A 1: List of sources of updated data 
 
  
Variable Description Database URL
Public health expenditure
General government expenditure on health in constant 
2010 US$ per capita, PPP
World Health Organization, Global Health Expenditure 
Data Base
http://apps.who.int/nha/database/ViewData/Indicators/en
Total health expenditure
Total expenditure on health in constant 2010 US$ per 
capita, PPP
World Health Organization, Global Health Expenditure 
Data Base
http://apps.who.int/nha/database/ViewData/Indicators/en
Private health insurance Private insurance in constant 2010 US$ per capita, PPP
World Health Organization, Global Health Expenditure 
Data Base
http://apps.who.int/nha/database/ViewData/Indicators/en
Out of pocket health 
expenditure
Out of pocket expenditure in constant (2005) US$ per 
capita, PPP
World Health Organization, Global Health Expenditure 
Data Base
http://apps.who.int/nha/database/ViewData/Indicators/en
Immunization: measles Immunization, measles (% of children ages 12-23 months) World Bank, World Development Indicators database http://data.worldbank.org/indicator/SH.IMM.MEAS/countries
Immunization coverage (other 
than measles)
WHO/UNICEF coverage estimates for 1980-2014, as of July 
2015.; Reported official target population, number of doses 
administrered and official coverage
World Health Organization, Immunization, Vaccines and 
Biologicals Data
http://www.who.int/immunization/monitoring_surveillance/
data/en/
Adult female mortality rate Mortality rate, adult, female (per 1,000 female adults) World Bank, World Development Indicators database http://data.worldbank.org/indicator/SP.DYN.AMRT.FE
Adult male mortality rate Mortality rate, adult, male (per 1,000 male adults) World Bank, World Development Indicators database http://data.worldbank.org/indicator/SP.DYN.AMRT.MA
Under 5 mortality rate (UN 
estimate)
Mortality rate, under-5 (per 1,000 live births) World Bank, World Development Indicators database http://data.worldbank.org/indicator/SH.DYN.MORT
Under 5 mortality rate (IHME 
estimate)
Mortality rate, under-5 (per 1,000 live births): Infant and 
Child Mortality Estimates by country
Institute of Health Metrics and Evaluation, Global Health 
Data Exchange
http://ghdx.healthdata.org/record/infant-and-child-mortality-
estimates-country-1970-2010
Maternal mortality rate
Maternal mortality ratio (modeled estimate, per 100,000 
live births)
World Bank, World Development Indicators database http://data.worldbank.org/indicator/SH.STA.MMRT
Gross domestic product (GDP) GDP per capita, constant 2011 US$, PPP World Bank, World Development Indicators database http://data.worldbank.org/indicator/NY.GDP.PCAP.KD
Primary education enrollment 
rate
Adjusted net enrollment rate, primary (% of primary school 
age children)
World Bank, World Development Indicators database
http://data.worldbank.org/indicator/SE.PRM.TENR?page=4&d
isplay=defaut3Fiframe3Dtrue
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Table A 1: List of sources of updated data (continued) 
Variable Description Database URL
Population aged 0-14 Population ages 0-14 (% of total) World Bank, World Development Indicators database http://data.worldbank.org/indicator/SP.POP.0014.TO.ZS
Population aged 65+ Population ages 65 and above (% of total) World Bank, World Development Indicators database http://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS
CO2 emission per capita CO2 emissions (metric tons per capita) World Bank, World Development Indicators database http://data.worldbank.org/indicator/EN.ATM.CO2E.PC
Battle related deaths Number of battle-related deaths by country Uppsala University, UCDP Battle-related Deaths dataset
http://www.pcr.uu.se/research/ucdp/datasets/ucdp_battle-
related_deaths_dataset/
WHO external cause of death 8 indicators of deaths which are externaly caused
World Health Organization, Global Health Expenditure 
Data Base
http://www.who.int/healthinfo/mortality_data/en/
WDI worldwide governance 
indicators
governmental performance World Bank, Worldwide Governance Indicators data http://info.worldbank.org/governance/wgi/index.aspx#home
Total population Population, total World Bank, World Development Indicators database http://data.worldbank.org/indicator/SP.POP.TOTL
SIPRI military expenditure Military expenditure in 2011 constant USD
Stockholm International Peace Research Institute Military 
Expenditure Database
http://www.sipri.org/research/armaments/milex/milex_data
base
Legal origins of country
Legal origins of countries (Brithsh, French, Socialist, 
German, and Scandinavian)
World Bank Global Development Network Growth 
Database: Lost decades social indicaotors and fixed 
factors
http://econ.worldbank.org/WBSITE/EXTERNAL/EXTDEC/EXTRE
SEARCH/0,,contentMDK:20701055~pagePK:64214825~piPK:642
14943~theSitePK:469382,00.html
Urban population rate Urban population (% of total) World Bank, World Development Indicators database http://data.worldbank.org/indicator/SP.URB.TOTL.IN.ZS
Sanitation rate Improved sanitation facilities (% of population with access) World Bank, World Development Indicators database http://data.worldbank.org/indicator/SH.STA.ACSN
Paved road rate % paved road
United Nations Database (mirroing World Development 
Indicators database)
http://data.un.org/Data.aspx?d=WDI&f=Indicator_Code%3AIS
.ROD.PAVE.ZS
Literacy rate literacy rate (% of people ages 15 and above) World Bank, World Development Indicators database http://data.worldbank.org/indicator/SE.ADT.LITR.ZS
Primary education completion 
rate
% of the total population of the theoretical entrance age to 
the last grade of primary education
World Bank, World Development Indicators database http://data.worldbank.org/indicator/SE.PRM.CMPT.ZS
Donor funding on basic health Development assistance for health (DAH)
Institute of Health Metrics and Evaluation, Global Health 
Data Exchange
http://ghdx.healthdata.org/record/development-assistance-
health-database-1990-2014
Consumption-investment ratio
Investment Share of PPP Converted GDP Per Capita at 2005 
constant prices 
University of Pennsilvania, Penn World Tables
https://pwt.sas.upenn.edu/php_site/pwt71/pwt71_form.ph
p
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Table A 2: BGG analysis using the original data (replacing every variable from updated data sequentially) 
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Table A 3: BGG analysis using the original data (replacing every variable from updated data sequentially): updated data are imputed using original data where missing 
Assessing the impact of health care expenditures on mortality using cross-country data  35 
 
 
Table A 4: MSS analysis using the original data (replacing every variable from updated data sequentially) 
 
  
CO2 
emission
Conflict 
death Education
GDP per 
capita
Public 
health 
expenditure
Adult 
female 
mortality
Adult 
male 
mortality
Under 5 
mortality
Population 
under 14
Population 
over 65
A. Under 5 Mortality
(1) (2) (3) (4) (5) (6) (7) (8) (9) (10)
Public health expenditure 1.105*** -17.663** -9.323** 2.496*** -14.774** -13.779** -13.779** -13.779** -14.165** -12.671**
(0.325) (8.050) (3.755) (0.615) (6.342) (5.794) (5.794) (5.794) (6.029) (5.187)
First stage F of reverse equation 2.818 1.842 0.485 1.197 3.070 3.070 3.070 3.070 2.870 2.703
First stage F of main equation 16316.984 5.783 10.581 582.578 6.447 7.402 7.402 7.402 7.145 8.040
N 1404 1398 1346 1375 1398 1398 1398 1398 1398 1398
B. Adult female mortality
(1) (2) (3) (4) (5) (6) (7) (8) (9) (10)
Public health expenditure -4.785** -2.523*** 5.007 -5.778** -2.818** -27.641** -3.957** -3.957** -1.158* -2.667***
(1.935) (0.943) (3.297) (2.601) (1.130) (12.696) (1.552) (1.552) (0.689) (1.000)
First stage F of reverse equation 7.485 14.846 0.571 8.447 7.341 3.991 7.341 7.341 6.333 7.304
First stage F of main equation 1904.345 57128.000 236.640 533.398 7759.480 10.180 4857.691 4857.691 5751295.449 37410.162
N 1229 1223 1165 1204 1223 1398 1223 1223 1223 1223
C. Adult male mortality
Public health expenditure -4.954*** -1.927*** 2.010 -4.766** -14.774** -2.944*** -19.772** -2.944*** -0.794 -1.745***
(1.841) (0.670) (1.369) (1.890) (6.342) (1.026) (7.745) (1.026) (0.532) (0.655)
First stage F of reverse equation 11.767 17.764 0.880 14.104 3.070 12.021 6.542 12.021 10.708 11.880
First stage F of main equation 1091.073 155334.965 3138.602 874.922 6.447 13790.401 19.354 13790.401 1095374.893 183319.494
N 1229 1223 1165 1204 1398 1223 1398 1223 1223 1223
Variable replaced
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Table A 5: MSS analysis using the original data (replacing every variable from updated data sequentially): updated data are imputed using original data where missing 
 
 
CO2 
emission
Conflict 
death Education
GDP per 
capita
Public 
health 
expenditure
Adult 
female 
mortality
Adult 
male 
mortality
Under 5 
mortality
Population 
under 14
Population 
over 65
A. Under 5 Mortality
(1) (2) (3) (4) (5) (6) (7) (8) (9) (10)
Public health expenditure 1.105*** -17.663** -4.335*** 3.121*** -14.774** -13.779** -13.779** -13.779** -14.165** -12.671**
(0.325) (8.050) (1.573) (0.778) (6.342) (5.794) (5.794) (5.794) (6.029) (5.187)
First stage F of reverse equation 2.818 1.842 4.249 1.558 3.070 3.070 3.070 3.070 2.870 2.703
First stage F of main equation 16316.984 5.783 36.995 217.160 6.447 7.402 7.402 7.402 7.145 8.040
N 1404 1398 1512 1398 1398 1398 1398 1398 1398 1398
B. Adult female mortality
(1) (2) (3) (4) (5) (6) (7) (8) (9) (10)
Public health expenditure -4.785** -2.523*** -5.186** -6.245** -2.818** -27.641** -3.957** -3.957** -1.158* -2.667***
(1.935) (0.943) (2.153) (2.796) (1.130) (12.696) (1.552) (1.552) (0.689) (1.000)
First stage F of reverse equation 7.485 14.846 6.796 7.842 7.341 3.991 7.341 7.341 6.333 7.304
First stage F of main equation 1904.345 57128.000 1018.047 412.293 7759.480 10.180 4857.691 4857.691 5751295.449 37410.162
N 1229 1223 1320 1223 1223 1398 1223 1223 1223 1223
C. Adult male mortality
Public health expenditure -4.954*** -1.927*** -4.887*** -5.390** -14.774** -2.944*** -19.772** -2.944*** -0.794 -1.745***
(1.841) (0.670) (1.792) (2.096) (6.342) (1.026) (7.745) (1.026) (0.532) (0.655)
First stage F of reverse equation 11.767 17.764 11.404 12.536 3.070 12.021 6.542 12.021 10.708 11.880
First stage F of main equation 1091.073 155334.965 1073.583 620.003 6.447 13790.401 19.354 13790.401 1095374.893 183319.494
N 1229 1223 1320 1223 1398 1223 1398 1223 1223 1223
Variable replaced
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Table A 6: Traditional IV approach (with streamlined model) using different specifications of instrumental 
variables 
 
Notes: 
IVs in the main model (Table 6 of the main paper) are log neighbours military expenditure as % of GDP, and log neighbours 
public health expenditure as % of GDP. 
x Model (1) uses Raw IV (note that main model in Table 6 used logged IVs) 
x Model (2) adds squared raw IV to model (1) 
x Model (3) further adds cubic raw IV to model (2) 
x Model (4) uses total neighbours military and public health expenditure (not per capita expenditure) 
 
Table A 7: Bruckner IV approach (with streamlined model) using different specifications of instrumental 
variables 
 
Notes: 
IVs in the main model (Table 6 of the main paper) are log per capita CO2 emission; and log number of deaths by conflict   
x Model (1) uses Raw IV (note that main model in Table 6 used logged IVs) 
x Model (2) adds squared raw IV to model (1) 
x Model (3) further adds cubic raw IV to model (2) 
x Model (4) uses main IV (CO2 and Conflict deaths) plus log of external causes of deaths
A: Under 5 mortality
(1) (2) (3) (4) (1) (2) (3) (4)
log Public health expenditure -0.048 -0.003 0.038 0.193 1.069 0.035 -0.060 0.560
(0.310) (0.291) (0.266) (1.801) (1.413) (0.265) (0.196) (1.912)
First stage F 0.664 0.707 0.503 0.079 0.506 1.564 3.221 0.157
N 661 661 661 661 2601 2601 2601 2601
B: Adult female mortality
(1) (2) (3) (4) (1) (2) (3) (4)
log Public health expenditure -0.118 -0.315 -0.264 -0.303 0.381 0.271 0.233 0.448
(0.420) (0.439) (0.410) (1.470) (0.526) (0.245) (0.189) (1.373)
First stage F 0.546 0.757 0.537 0.076 0.506 1.564 3.221 0.157
N 642 642 642 642 2601 2601 2601 2601
C: Adult male mortality
(1) (2) (3) (4) (1) (2) (3) (4)
log Public health expenditure -0.174 -0.447 -0.471 -0.501 0.284 0.328 0.312* 0.802
(0.354) (0.344) (0.347) (1.507) (0.410) (0.218) (0.169) (1.790)
First stage F 0.546 0.757 0.537 0.076 0.506 1.564 3.221 0.157
N 642 642 642 642 2601 2601 2601 2601
Unimputed model Imputed model
A: Under 5 mortality
(1) (2) (3) (4) (1) (2) (3) (4)
log Public health expenditure -0.765*** -0.493*** -0.227*** -0.040 -0.272** -0.193** -0.060 -0.117***
(0.157) (0.092) (0.045) (0.050) (0.120) (0.091) (0.039) (0.035)
First stage F of reverse equation 1.679 0.845 1.322 1.199 1.836 1.324 1.597 2.562
First stage F of main equation 51.819 141.607 1355.738 12557.842 36.317 85.065 3427.838 8886.840
N 669 669 669 392 2631 2631 2631 1214
B: Adult female mortality
(1) (2) (3) (4) (1) (2) (3) (4)
log Public health expenditure -0.262*** -0.237*** -0.305*** 0.039 -0.240** -0.117* -0.049 0.122***
(0.060) (0.056) (0.068) (0.036) (0.121) (0.068) (0.039) (0.046)
First stage F of reverse equation 2.432 1.686 2.356 3.826 1.975 5.044 3.792 1.297
First stage F of main equation 252.397 331.238 172.733 14293.717 19.599 89.859 693.625 808.783
N 650 650 650 376 2590 2590 2590 1182
C: Adult male mortality
(1) (2) (3) (4) (1) (2) (3) (4)
log Public health expenditure -0.346*** -0.192*** -0.263*** -0.016 -0.392*** -0.301** -0.086 0.079***
(0.070) (0.048) (0.058) (0.035) (0.145) (0.125) (0.064) (0.027)
First stage F of reverse equation 1.139 1.693 3.137 4.676 1.180 2.990 2.095 1.371
First stage F of main equation 102.915 360.303 172.024 378266.2 14.540 15.566 67.351 2690.143
N 650 650 650 376 2635 2635 2635 1214
Unimputed model Imputed model
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Table A 8: Regression analysis based on quinquennial data (replication of the analysis in Table 6, first column with fixed effect IV model) 
  
Notes:  
x Model (1) and (2) show the results based on the data from 1995, 2000, 2005 and 2010 (5-year interval data), with and without data imputation, respectively. 
x Model (3) and (4) show the results based on the data where five-year average of the variables (1995-1999; 2000-2004; 2005-2009; and 2010-2011) are calculated and used in the 
regression, with and without data imputation, respectively. 
A: log under 5 mortality
(1) (2) (3) (4) (1) (2) (3) (4)
log Public health expenditure -0.709 -0.522 0.365 0.498 0.188* -0.408*** -0.237*** -0.135*
(0.584) (7.415) (0.542) (0.555) (0.108) (0.121) (0.065) (0.081)
First stage F of reverse equation . . . . 4.782 2.234 1.657 3.749
First stage F of main equation 1.300 0.385 0.658 0.839 222.019 46.742 748.225 315.139
Data imputation No Yes No Yes No Yes No Yes
N 133 612 308 612 131 618 308 620
B: log adult female mortality
(1) (2) (3) (4) (1) (2) (3) (4)
log Public health expenditure 0.403 -0.460 0.178 0.078 0.201* 0.483*** 0.689*** 0.222**
(0.869) (8.255) (0.553) (0.268) (0.110) (0.159) (0.182) (0.086)
First stage F of reverse equation . . . . 0.958 1.048 0.224 1.256
First stage F of main equation 0.581 0.385 0.392 0.839 153.770 18.868 31.989 64.353
Data imputation No Yes No Yes No Yes No Yes
N 119 612 298 612 119 603 298 607
C: log adult male mortality
(1) (2) (3) (4) (1) (2) (3) (4)
log Public health expenditure 0.188 -0.291 0.346 0.120 -0.298** -0.259*** -0.095** 0.043
(0.684) (6.252) (0.514) (0.229) (0.112) (0.090) (0.047) (0.032)
First stage F of reverse equation . . . . 0.953 1.631 0.105 2.019
First stage F of main equation 0.581 0.385 0.392 0.839 64.963 35.783 895.420 12969.315
Data imputation No Yes No Yes No Yes No Yes
N 119 612 298 612 119 603 298 607
Traditional IV Bruckner IV
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Table A 9: Traditional IV approach (with streamlined model) in which log GDP per capita is treated as an 
endogenous variable 
 
EŽƚĞƐ P/ŶƐƚƌƵŵĞŶƚĂůǀĂƌŝĂďůĞƐĨŽƌůŽŐWƵďůŝĐŚĞĂůƚŚĞǆƉĞŶĚŝƚƵƌĞĂƌĞƚŚĞƐĂŵĞĂƐƚŚĞdĂďůĞ ? ?ŶĞŝŐŚďŽƵƌƐ ?ŵŝůŝƚĂƌǇ
ĞǆƉĞŶĚŝƚƵƌĞĂƐA?ŽĨ'WĂŶĚŶĞŝŐŚďŽƵƌƐ ?ƉƵďůŝĐŚĞĂůƚŚĞǆƉĞŶĚŝƚƵƌĞĂƐA?ŽĨ'W ? ?&ŽůůŽǁŝŶŐŽŬŚĂƌŝĞƚĂů ? ? ? ? ? ? ? ?ƚŚĞ
instrumental variable for log GDP per capita is the Consumption-Investment ratio of the country (available from Penn 
World Table, accessed in August 2015). 
 
 
  
A: log under 5 mortality
(1) (2) (3) (4)
log Public health expenditure 0.297 0.188 0.660 0.007
(0.519) (0.296) (0.600) (0.222)
log GDP per capita -0.055 -0.834* -1.262 -0.402**
(0.846) (0.439) (0.785) (0.188)
F for log Public health expenditure 1.263 2.573 0.849 1.666
F for log GDP per capita 0.728 2.964 0.860 3.060
Data imputation No Yes No Yes
N 617 2415 607 2335
B: log adult female mortality
(1) (2) (3) (4)
log Public health expenditure 0.267 0.001 0.081 -0.014
(0.517) (0.212) (0.400) (0.212)
log GDP per capita 0.041 -0.177 -0.236 -0.045
(0.952) (0.302) (0.442) (0.174)
F for log Public health expenditure 1.344 2.573 0.857 1.666
F for log GDP per capita 0.605 2.964 0.863 3.060
Data imputation No Yes No Yes
N 606 2415 597 2335
C: log adult male mortality
(1) (2) (3) (4)
log Public health expenditure 0.116 -0.007 0.094 -0.160
(0.362) (0.166) (0.401) (0.183)
log GDP per capita -0.003 -0.164 -0.410 -0.072
(0.582) (0.253) (0.414) (0.168)
F for log Public health expenditure 1.344 2.573 0.857 1.666
F for log GDP per capita 0.605 2.964 0.863 3.060
Data imputation No Yes No Yes
N 606 2415 597 2335
Fixed effect Pooled cross section
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Figure A 1: Heterogeneity of the impact of public health expenditure on mortality based on the BGG 
specification, using year 2000 updated data 
 
Note: Based on the BGG model (column (4) of Table 4), we estimated the impact of public health expenditure on mortality 
outcomes, allowing for variations by the level of economic development (proxied by the proportion of paved roads) and by 
donor funding on health. The histograms are based on 127 countries which are included in the regression analysis. 
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Appendix B - Alternative estimation strategies explored 
B.1 Allowing for lagged impacts of public health expenditure 
A potential reason why we fail (as did some previous studies e.g. Filmer and Prichett, 1999) to 
confirm a negative impact of public health expenditure on health could be due to our model 
estimating the impact of current expenditure on current health outcome. Indeed there may well be 
lags between healthcare investment and its impact upon population health. To allow for this 
possibility, we now account for lagged impacts of public health expenditure in the streamlined 
model. Instead of contemporaneous health expenditure, we now use lagged expenditure (t-1, t-2 
and t-5) in the equation as endogenous variables.  
  
B.2 Substitution between public and private expenditure 
Another potential reason why we do not find robust enough results to support the expectation that 
public health expenditures consistently and significantly reduce mortality rates may be that as public 
health care spending increases, individuals are likely to respond by reducing their previously private 
expenditures (from out-of-pocket or privately insured sources). As a result the overall resources 
available to the health care system may not increase as much, compared to a situation in which 
there would be no such substitution effect, and, hence, unless the marginal productivity of public 
spending vastly outperforms that of private spending, the overall mortality or health effect 
associated with a given increase in public health expenditures may be limited or non-existent. While 
ideally we would want to explicitly model the interrelationship between public and private health 
expenditures, this is beyond the scope of the present exercise. Instead, in order to circumvent the 
explicit modelling of the interrelationship it may be instructive to examine the impact of total health 
expenditure on mortality rates. At least, this would allow us to see whether we are in a position to 
detect any relationship between expenditures and outcomes, and if that was the case, this could be 
seen as indirect evidence of the importance of a substitution effect.  
 
B.3 Allowing for more lagged structure for the impacts of public health expenditure 
We further investigate the potential lagged structure by including lagged public health expenditure 
(t, t-1, t-2, and t-3) at the same time in the regression models. These models capture the impacts of 
ƉƌĞǀŝŽƵƐǇĞĂƌƐ ?ĞǆƉĞŶĚŝƚƵƌĞŽŶŵŽƌƚĂůŝƚǇŝŶƚŚĞĐƵƌƌĞŶƚǇĞĂƌ ?ĐŽŶĚŝƚŝŽŶĂůŽŶƚŚĞŝŵƉĂĐƚŽĨƚŚĞ
expenditure in the current year. For both Traditional and Bruckner IV approach, the lagged values of 
the instrumental variables are used as IVs of the lagged public health expenditure, i.e. the IV of the 
lagged expenditure (t-1) is the lagged IV (t-1). 
 
B.4 Further estimation approaches 
In Block D of Appendix Table B3, we present the estimation results based on a dynamic panel 
approach - Blundell-Bond estimation. In this approach, a 1-year lagged mortality rate is included as 
an explanatory variable as well as public health expenditure and the same set of covariates (no lag 
were taken for these variables): Ǥ O? O?ǣ୨୲ ൌ Ⱦ୨ ൅ ɏ୨ǡ୲ିଵ ൅ Ⱦଵ୨୲ ൅ ܆୨୲ᇱ ઺ ൅ ߝ௝௧Ǥ  
Taking the first difference for all variables in Eq. (4) eliminates the country level fixed effect Ⱦ୨ . The 
first-differenced error term ߝ௝௧ െ ߝ௝ǡ௧ିଵ is uncorrelated with second or further lags of mortality, 
health expenditure and the other variables. We use these properties as the moment conditions in 
the estimation of the model by system Generalised Method of Moments.30 
                                                          
30
 Note that, in this dynamic panel data approach, we are only interested in the impact of contemporaneous public health 
expenditure on contemporaneous mortality. The impact dMOt/dEXt is given by the single coefficient beta. 
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Table B 1: Impact of lagged, and total public health expenditure on mortality (streamlined model using instrumental variable approach) 
 
Notes: In Block A, B and C, the first stage F of the reverse causality model in the Bruckner IV approach is not presented in the table. Following Moreno-Serra and Smith (2015), once the 
residual from the reverse causality model is estimated (see Eq.(3) in Method section), its lag is calculated and used as instrumental variable in the main regression model.   
A: Impact of 1-year lagged health expenditure 
(1) (2) (3) (4) (1) (2) (3) (4) (1) (2) (3) (4)
log health expenditure (t-1) -0.262 0.720 0.036 -0.199** -0.408 0.208 1.238* 0.019 -0.344 0.131 0.148*** -0.120
(0.462) (0.766) (0.040) (0.093) (0.671) (0.318) (0.722) (0.012) (0.532) (0.252) (0.043) (0.075)
First stage F of expenditure (t-1) 0.690 0.712 2804.160 61.301 0.458 0.712 3.871 10690547.8 0.458 0.712 80.659 31.121
Imputation No Yes No Yes No Yes No Yes No Yes No Yes
N 661 2447 382 2476 642 2447 369 2451 642 2447 369 2451
B: Impact of 2-year lagged health expenditure
(1) (2) (3) (4) (1) (2) (3) (4) (1) (2) (3) (4)
log health expenditure (t-2) -0.218 0.669 0.061 -0.177** -0.118 0.081 1.664 0.015 -0.132 0.053 0.155*** -0.094
(0.252) (0.741) (0.046) (0.083) (0.246) (0.252) (1.479) (0.012) (0.214) (0.217) (0.051) (0.066)
First stage F of expenditure (t-2) 1.878 0.746 1516.7 71.363 1.426 0.746 1.382 9753700.8 1.426 0.746 54.508 32.963
Imputation No Yes No Yes No Yes No Yes No Yes No Yes
N 603 2295 413 2321 585 2295 400 2308 585 2295 400 2308
C: Impact of 5-year lagged health expenditure
(1) (2) (3) (4) (1) (2) (3) (4) (1) (2) (3) (4)
log health expenditure (t-5) -0.036 -0.281 -0.033 -0.113** -0.157 -0.308 1.299 0.011 -0.014 -0.394 0.080 -0.036
(0.116) (0.465) (0.045) (0.056) (0.109) (0.361) (1.071) (0.010) (0.074) (0.393) (0.054) (0.039)
First stage F of expenditure (t-5) 2.892 0.921 889.299 88.489 2.991 0.921 1.728 8346576 2.991 0.921 28.507 38.357
Imputation No Yes No Yes No Yes No Yes No Yes No Yes
N 556 1832 226 1856 538 1832 214 1844 538 1832 214 1844
D: Impact of total health expenditure 
(1) (2) (3) (4) (1) (2) (3) (4) (1) (2) (3) (4)
log total health expenditure -0.197 0.606 -0.093* -0.299*** -0.404 -0.486 0.018 0.228*** -0.232 -0.219 -0.331*** 0.021
(1.174) (2.009) (0.048) (0.045) (0.864) (0.894) (0.037) (0.052) (0.624) (0.774) (0.083) (0.031)
First stage F of reverse equation . . 1.262 3.696 . . 0.096 4.461 . . 1.293 3.696
First stage F of main equation 0.393 0.244 36756.8 1776.2 0.491 0.244 373761.6 635.921 0.491 0.244 122.514 129224.7
Imputation No Yes No Yes No Yes No Yes No Yes No Yes
N 661 2601 666 2631 642 2601 647 2590 642 2601 647 2590
log under 5 mortality log adult female mortality log adult male mortality
Traditional IV Bruckner IV Traditional IV Bruckner IV Traditional IV Bruckner IV
log under 5 mortality log adult female mortality log adult male mortality
Traditional IV Bruckner IV Traditional IV Bruckner IV Traditional IV Bruckner IV
log under 5 mortality log adult female mortality log adult male mortality
Traditional IV Bruckner IV Traditional IV Bruckner IV Traditional IV Bruckner IV
log under 5 mortality log adult female mortality log adult male mortality
Traditional IV Bruckner IV Traditional IV Bruckner IV Traditional IV Bruckner IV
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Table B 2: Impact of present and lagged health expenditure on mortality (streamlined model using instrumental variable approach) 
 
A: Impact of contemporaneous and lagged (1 year only) health expenditure 
(1) (2) (3) (4) (1) (2) (3) (4) (1) (2) (3) (4)
log health expenditure (t) 0.267 0.610 0.064 -0.153*** 0.390 0.300 1.720* 0.017** 0.490 0.253 0.304*** -0.104***
(0.487) (0.592) (0.042) (0.051) (0.721) (0.223) (1.021) (0.008) (0.709) (0.180) (0.096) (0.035)
log health expenditure (t-1) -0.367 0.042 0.008 -0.088 -0.400 -0.085 0.648 0.007 -0.393 -0.096 0.010 -0.048
(0.287) (0.514) (0.035) (0.067) (0.244) (0.245) (0.714) (0.011) (0.238) (0.200) (0.046) (0.057)
First stage F of expenditure (t) 0.576 1.712 7776.995 512.554 0.290 1.712 5.622 2.916e+08 0.290 1.712 58.792 1156.531
First stage F of expenditure (t-1) 2.225 1.797 41340.818 450.828 2.054 1.797 9.018 2.197e+08 2.054 1.797 79.947 750.556
Imputation No Yes No Yes No Yes No Yes No Yes No Yes
N 661 2447 382 2476 642 2447 369 2434 642 2447 369 2434
B: Impact of contemporaneous and lagged (1 and 2 years) health expenditure 
(1) (2) (3) (4) (1) (2) (3) (4) (1) (2) (3) (4)
log health expenditure (t) 0.376 0.322 0.096** -0.166*** 0.459 0.019 2.795 0.010 0.378 0.050 0.278*** -0.113***
(0.488) (0.341) (0.045) (0.047) (0.734) (0.136) (4.173) (0.009) (0.665) (0.123) (0.097) (0.034)
log health expenditure (t-1) -0.075 0.193 -0.022 -0.009 -0.424 0.107 1.708 0.010** -0.445 0.066 0.041 -0.008
(0.397) (0.285) (0.027) (0.026) (0.555) (0.112) (4.342) (0.004) (0.520) (0.095) (0.058) (0.014)
log health expenditure (t-2) -0.357 -0.237 -0.031 -0.088 -0.060 -0.249 1.839 0.003 -0.058 -0.218 -0.029 -0.036
(0.240) (0.395) (0.039) (0.057) (0.293) (0.161) (4.033) (0.010) (0.269) (0.141) (0.055) (0.049)
First stage F of expenditure (t) 0.628 2.152 10571.0 2086.008 0.539 2.152 0.866 3.522e+08 0.539 2.152 52.780 1029.291
First stage F of expenditure (t-1) 0.987 1.736 43483.6 1592.700 0.801 1.736 0.421 6.542e+08 0.801 1.736 49.621 938.015
First stage F of expenditure (t-2) 2.423 1.835 29486.1 2415.063 2.243 1.835 0.814 4.166e+08 2.243 1.835 75.358 814.302
Imputation No Yes No Yes No Yes No Yes No Yes No Yes
N 603 2295 304 2321 585 2295 292 2280 585 2295 292 2280
C: Impact of contemporaneous and lagged (1, 2 and 3 years) health expenditure 
(1) (2) (3) (4) (1) (2) (3) (4) (1) (2) (3) (4)
log health expenditure (t) 0.318 -0.030 0.148*** -0.076** 0.420 -0.073 1.006** -0.073 0.260 -0.065 0.285*** -0.065
(0.419) (0.193) (0.038) (0.030) (0.602) (0.116) (0.476) (0.116) (0.512) (0.103) (0.089) (0.103)
log health expenditure (t-1) -0.143 0.045 -0.003 -0.023 -0.341 -0.017 0.138 -0.017 -0.347 -0.014 -0.004 -0.014
(0.321) (0.165) (0.027) (0.016) (0.390) (0.098) (0.415) (0.098) (0.357) (0.086) (0.048) (0.086)
log health expenditure (t-2) -0.263 0.126 0.007 -0.013 -0.189 0.118 0.463 0.118 -0.178 0.075 -0.001 0.075
(0.226) (0.205) (0.023) (0.012) (0.213) (0.105) (0.577) (0.105) (0.165) (0.093) (0.052) (0.093)
log health expenditure (t-3) 0.034 0.105 -0.029 -0.053 0.045 -0.254* 0.441 -0.254* 0.078 -0.219* 0.022 -0.219*
(0.182) (0.243) (0.036) (0.040) (0.216) (0.150) (0.737) (0.150) (0.181) (0.131) (0.050) (0.131)
First stage F of expenditure (t) 0.733 3.473 10578.6 34655.090 0.691 3.473 4.380 3.473 0.691 3.473 68.129 3.473
First stage F of expenditure (t-1) 2.042 2.555 125656.0 107866.910 1.757 2.555 3.524 2.555 1.757 2.555 70.385 2.555
First stage F of expenditure (t-2) 1.782 1.762 40257.7 829780.259 1.710 1.762 3.648 1.762 1.710 1.762 30.885 1.762
First stage F of expenditure (t-3) 1.284 1.820 33858.4 230538.810 1.361 1.820 2.131 1.820 1.361 1.820 73.709 1.820
Imputation No Yes No Yes No Yes No Yes No Yes No Yes
N 603 2142 226 2138 585 226 2142 585 2142 226 2142
log under 5 mortality log adult female mortality log adult male mortality
Traditional IV Bruckner IV Traditional IV Bruckner IV Traditional IV Bruckner IV
log under 5 mortality log adult female mortality log adult male mortality
Traditional IV Bruckner IV Traditional IV Bruckner IV Traditional IV Bruckner IV
log under 5 mortality log adult female mortality log adult male mortality
Traditional IV Bruckner IV Traditional IV Bruckner IV Traditional IV Bruckner IV
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Table B 3: Alternative estimation approaches (fixed effect plus lagged expenditure; dynamic panel 
specification) 
 
 
 
 
 
 
 
  
A: Impact of contemporaneous health expenditure: Fixed effect model  
(1) (2) (1) (2) (1) (2)
log health expenditure -0.026 -0.005 -0.026 0.025** -0.021 0.042**
(0.035) (0.020) (0.029) (0.011) (0.026) (0.018)
Imputation No Yes No Yes No Yes
N 688 2635 669 2635 669 2635
B: Impact of 1-year lagged health expenditure: Fixed effect model
(1) (2) (1) (2) (1) (2)
log health expenditure (t-1) -0.044 -0.015 -0.022 0.020* -0.015 0.038*
(0.029) (0.021) (0.025) (0.012) (0.022) (0.020)
Imputation No Yes No Yes No Yes
N 687 2479 668 2479 668 2479
C: Impact of 2-year lagged health expenditure: Fixed effect model
(1) (2) (1) (2) (1) (2)
log health expenditure (t-2) -0.052* -0.024 -0.028 0.017 -0.025 0.035*
(0.030) (0.023) (0.026) (0.011) (0.022) (0.020)
Imputation No Yes No Yes No Yes
N 636 2325 618 2325 618 2325
D: Impact of contemporaneous health expenditure: Blundell-Bond dynamic panel estimation
(1) (2) (1) (2) (1) (2)
lagged mortality (t-1) 1.058*** 1.128*** 1.063*** 1.061*** 1.058*** 1.033***
(0.166) (0.197) (0.046) (0.044) (0.129) (0.034)
log health expenditure -0.011 -0.021 -0.011 -0.019 0.065 -0.024
(0.331) (0.049) (0.009) (0.026) (0.185) (0.031)
Imputation No Yes No Yes No Yes
P value of Hansen test 0.791 0.002 0.478 0.001 0.361 0.008
P value of AR(1) test 0.808 0.269 0.003 0.006 0.038 0.006
P value of AR(2) test 0.709 0.701 0.272 0.229 0.348 0.204
Number of instruments 28 31 28 31 28 31
N 688 2480 669 2480 677 2480
log under 5 mortality log adult female mortality log adult male mortality
log under 5 mortality log adult female mortality log adult male mortality
log under 5 mortality log adult female mortality log adult male mortality
log under 5 mortality log adult female mortality log adult male mortality
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Appendix C ʹ Further descriptive statistics  
Table C 1: Descriptive statistics of BGG data (original data and updated data)  
 
 Notes: 
* 
In this column the analysis include as many countries as possible (max available number of countries is 238) from the 
updated data sources. 
 ?/ŶƚŚĞŽƌŝŐŝŶĂůĚĂƚĂ ?'WƉĞƌĐĂƉŝƚĂƵƐŝŶŐŝŶƚĞƌŶĂƚŝŽŶĂůĚŽůůĂƌƐĂƐŽĨ ? ? ? ?ŝƐƵƐĞĚ ?/ŶƚŚĞƵƉĚĂƚĞĚĚĂƚĂ ?'WƉĞƌĐĂƉŝƚĂ
using constant US dollars 2011 (PPP adjusted) is used.  
 ?/ŶƚŚĞŽƌŝŐŝŶĂůĚĂƚĂ ?ŐŽǀĞƌŶŵĞŶƚŚĞĂůƚŚĞǆƉĞŶĚŝƚƵƌĞƉĞƌĐĂƉŝƚĂ ?ŝŶƚĞƌŶĂƚŝŽŶĂů dollars as of 2000) is used. In the updated 
data, government health expenditure per capita in 2005 constant dollars is used.  
 
Table C 2: Descriptive statistics of MSS data (original data and updated data)  
  Notes: 
* 
In this column the analysis include as many countries as possible (max available number of countries is 229) from the 
updated data sources. 
 ?/ŶƚŚĞŽƌŝŐŝŶĂůĚĂƚĂ ?ŐŽǀĞƌŶŵĞŶƚŚĞĂůƚŚĞǆƉĞŶĚŝƚƵƌĞƉĞƌĐĂƉŝƚĂ ?ŝŶƚĞƌŶĂƚŝŽŶĂůĚŽůůĂƌƐĂƐŽĨ ? ? ? ? ?ŝƐƵƐĞĚ ?/ŶƚŚĞƵƉĚĂƚĞĚ
data, government health expenditure per capita in 2005 constant dollars is used. 
 ?/ŶƚŚĞŽƌŝŐŝŶĂůĚĂƚĂ ?'WƉĞƌĐĂƉŝƚĂƵƐŝŶŐŝŶƚĞƌŶĂƚŝŽŶĂůĚŽůůĂƌƐĂƐŽĨ ? ? ? ?ŝƐƵƐĞĚ ?/ŶƚŚĞƵƉĚĂƚĞĚĚĂƚĂ ?'WƉĞƌĐĂƉŝƚĂ
using constant US dollars 2011 (PPP adjusted) is used.  
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Table C 3: Descriptive statistics of the updated BGG data 2010 
 
Notes:  
*While in the original BGG data, per capita donor funding for health promotion from the Development Assistance Committee (DAC) of the Organization for Economic Co-operation and 
Development (OECD) in year 1998 is used. In the updated 2010 data, we instead use the data on per capita amount of Development Assistance for Health (DAH), available at the Institute of 
Health Metrics and Evaluation database.  
 ?/ŶƚŚĞŽƌŝŐŝŶĂůĚĂƚĂ ?'WƉĞƌĐĂƉŝƚĂƵƐŝŶŐŝŶƚĞƌŶĂƚŝŽŶĂůĚŽůůĂƌƐĂƐŽĨ ? ? ? ?ŝƐƵƐĞĚ ?/ŶƚŚĞƵƉĚĂƚĞĚĚĂƚĂ ?'DP per capita using constant US dollars 2011 (PPP adjusted) is used.  
 ?/ŶƚŚĞŽƌŝŐŝŶĂůĚĂƚĂ ?ŐŽǀĞƌŶŵĞŶƚŚĞĂůƚŚĞǆƉĞŶĚŝƚƵƌĞƉĞƌĐĂƉŝƚĂ ?ŝŶƚĞƌŶĂƚŝŽŶĂůĚŽůůĂƌƐĂƐŽĨ ? ? ? ? ?ŝƐƵƐĞĚ ?/ŶƚŚĞƵƉĚĂƚĞĚĚĂta, government health expenditure per capita in 2005 constant 
dollars is used. 
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Appendix D - Review of related studies using cross-country data 
Table D 1: Review of related studies using cross-country data 
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Table D 1: Review of related studies using cross-country data (continued) 
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Table D 1: Review of related studies using cross-country data (continued) 
 
